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Abstract 
Although habitual exercise can have profound beneficial effects on the cardiovascular 
system, there is a growing evidence base to suggest that single acute bouts of 
endurance exercise can lead to the release of cardiac biomarkers of damage and 
dysfunction. Whether this cardiac biomarker release is indicative of reversible or 
irreversible cardiomyocyte damage is not clear.  
The first study in this thesis employed a new high sensitivity assay to assess cardiac 
troponin (cTnI) as well as N terminal pro-brain natriuretic peptide (NT-proBNP) 
before, during and after 2 hr of treadmill exercise in young, healthy but non-athletic 
participants. No cTnI samples were elevated above the detection limit of the assay 
during exercise and only one participant had a detectable cTnI value post-exercise (22 
ng/L). NT-proBNP levels were elevated more consistently during exercise and 
recovery.   
In the second study, the repeatability of cardiac biomarker responses to 2 hr of 
treadmill exercise was assessed 1 and 12 weeks after an initial trial (Study 1). The 
same participant had an elevated cTnI value post-exercise in week 0 (22ng/L) and 
week 1 (30 ng/L).  All other participants had no detectable cTn in trials in week 0 and 
1. At week 12 one participant (different to the person in week 0 and 1) had elevated 
cTnI post-exercise (25 and 38 ng/l).  NT-proBNP levels rose with exercise in all trials 
but peaked earlier in trial 1 and demonstrated great individual variability.  
Study 3 and 4 investigated the role that ischemia may play in cardiac biomarker release 
and cardiac functional changes after endurance exercise. Ischemia was studied 
indirectly by employing remote ischemic preconditioning (RIPC) in a single-blind 
crossover research design.  In study 3 trained cyclists completed 2 one hour time trials 
in a controlled laboratory environment with trials preceded immediately RIPC or a 
SHAM protocol.  cTnI values were reduced after the RIPC trial compared to the 
SHAM during recovery from exercise (significant main effect for trial). NT-proBNP 
and indices of cardiac function were not mediated by RIPC. Using the same RIPC 
intervention in study 4 we employed a longer exercise task (160 km cycle) in trained 
cyclists. We confirmed a partial attenuation of cTnI appearance post-exercise following 
the RIPC intervention compared to the SHAM. In addition NT-proBNP was lower after 
the RIPC trial but RIPC did not mediate any change in cardiac function post-exercise. 
These data reflect the first tentative evidence that ischaemia could be implicated in 
post-exercise cardiac biomarker release.    
Although exercise can lead to cardiac biomarker appearance, and ischaemia may be 
implicated mechanistically, the rapid appearance and removal of these biomarkers as 
well as the limited impact on cardiac function still supports a reversible insult to the 
cardiomyocytes.  
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Chapter 1: 
Introduction  
 
1.1. Background Context 
Since the 1950s there have been numerous observational and intervention-based scientific 
studies that have examined the link between physical activity, physical fitness and 
cardiovascular health.  Cardiovascular Disease Statistics (2014) reported that heart and 
circulatory diseases were responsible for over a quarter of deaths (28%) in the UK in 
2012, with one in six male deaths and one in nine female deaths due to coronary heart 
disease (British Heart Foundation 2017). Importantly, these statistics noted that a total of 
nearly 74,000 deaths were attributed to a lack of regular physical activity.  In addition 
longitudinal studies, that have followed large sample populations, have shown that there 
is a protective effect of exercise and/or physical activity for numerous cardiovascular and 
non-cardiovascular chronic diseases such as diabetes, osteoporosis and many types of 
cancers (Fletcher et al., 2001).  An important additional consequence of this field of 
research is that groups that change their activity patterns though changes in active 
occupations or recreational levels have decreased morbidity and mortality rates (Myers et 
al., 2002).  This empirical evidence has led eminent panels such as the American College 
of Sports Medicine (ACSM) & the American Centres for Disease Control and Prevention 
(CDC) to provide consensus statements to support the positive link between exercise and 
positive health status (Pate et al., 1995; Fletcher et al., 2001; Myers et al., 2002). Overall, 
the current state of knowledge is that the more active, or fit, individuals are the less likely 
they are to suffer from primary or secondary cardiovascular disease, irrespective of 
gender, age and/or race/ethnicity (Morris et al., 1953; Paffenbarger et al., 1975; Pate et 
al., 1995; Myers et al., 2014).   
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Population-based understanding of the health benefits of exercise may partially explain 
the global increase in mass participation endurance sporting events (Baggish et al., 2011). 
Common endurance sporting activities include events such as marathons (42 km),  ultra-
marathons (161km) sportives (160 km) and multi-sport events such as triathlons (Ironman 
Triathlon: swim 3.86 km, bike for 180 km and run for 42 km). Event data shows a 
massive increase in participation in such activities over the last 20-30 years (Hoffman et 
al., 2011).  
 
It is, however, interesting that exercise prescription for health, often expounded from 
epidemiological databases and produced by ACSM and CDC (amongst many others), 
targets exercise prescription at volumes and intensities far below those employed by the 
amateur or elite athlete training for common endurance and ultra-endurance mass 
participation events.  The consequence of this dichotomy is that some attention is 
required as to the cardiovascular health benefits when exercise training or physical 
activity levels go way beyond those supported at a population level that induce positive 
cardiovascular outcomes. The question that may be posed is whether the relationship 
between “exercise dose” and cardiovascular health benefit is linear, curvilinear or of 
some other nature (Whyte et al., 2008). The full nature of the relationship between 
exercise and health status is still to be determined, with the intensity, duration and volume 
of physical activity required for optimal cardiovascular health is still to be clarified. 
  
The physical activity guidelines for 19 to 64 years olds to improve cardiovascular health 
is to either complete 150 minutes of moderate intensity exercise for 150 minutes or 75 
minutes of vigorous intensity exercise, or alternatively combination of moderate and 
vigorous intensity exercise over a week.  Interestingly, Blair et al., (1989) concluded that 
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the positive cardiovascular health effects of exercise may not be extended above an 
intensity of 10 metabolic equivalents (METS) or 35 ml/kg/min.  This exercise intensity 
may be below the level of which most amateur endurance athletes will need to train to 
improve performance.  If no cardiovascular health benefits are manifested at these 
exercise doses then a subsequent question is whether very high exercise loads have any 
negative cardiovascular health consequences? 
 
Contrary to the well-known health benefits of exercise training, there is a growing body 
of work that suggests exercise can contribute to an acute depression in cardiac function 
(Stenburg & Saltin, 1964; La Gerche et al., 2012; Sharma et al., 2011; Lord et al., 2015) 
as well as an acute release of cardiac biomarkers of damage and dysfunction (Shave et al., 
2007; Middleton et al., 2007).  There is also some tentative evidence that lifelong 
endurance exercise training can result in chronic changes such as myocardial fibrosis 
(Wilson et al., 2011; Eijsvogels et al., 2017) and an elevated risk of ECG abnormalities 
including atrial fibrillation (Karjalainen et al., 1999; Baldesberger et al., 2008; Anderson 
et al., 2013). Detailed analysis of individual studies provides some development of the 
issues concerning higher levels of performance and volumes of training.  For example, 
Anderson et al., (2013) noted that in Nordic skiers completing specific events; 1) the 
higher the exercise intensity the higher the risk of arrhythmia, 2) athletes that completed 
the event five or more times showed a 29 percentage increase in prevalence of arrhythmia 
and 3) athlete that had a higher finishing position had a higher risk of arrhythmia.  A 
combination of increasing participation in (ultra)endurance events and the awareness, in 
both scientific and lay environments, of potential cardiovascular consequences of such 
high levels of physical activity has resulted in a “living lab” approach to this topic.  In 
essence, many mass-participation (ultra) endurance events have allowed research to take 
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place alongside participation.  This provides unique insights into a small but growing part 
of the sport/exercise population.  Whilst cross-sectional in nature, such as the Anderson et 
al., (2013) study, unique data are being generated that are prompting on-going research 
and generating new hypotheses to test. 
 
One topic area that has utilised this “living laboratory” approach is the phenomenon that 
acute bouts of exercise can lead to either a decrease in cardiac function (normally 
assessed via echocardiography) or an elevation in blood levels of cardiac biomarkers 
indicative of cardiac myocyte damage or cardiac dysfunction (Shave et al ., 2010). On the 
basis that cardiac biomarkers have an important role to play in the diagnosis of coronary 
syndromes, as well as being linked to disease severity, it is somewhat counterintuitive and 
surprising that there have been numerous reports in the medical and scientific literature of 
elevated cardiac biomarkers after acute bouts of exercise (Shave et al., 2010).  The 
increase in cardiac troponins (cTnT, cTnI) and/or brain natriuretic peptides (NT-proBNP) 
with acute exercise has fuelled scientific and media speculation that there may be 
negative health effects of (ultra) endurance training and competition, although no causal 
data supports this supposition at this point.  To date information available in this sphere is 
both complex and contradictory with research presenting between 0% (Cummins et al., 
1987) and 100% (Middleton et al., 2008) prevalence rates for the elevation of cTnT and 
cTnI above detection levels of the assay during or after prolonged exercise.  This wildly 
variable and contradictory extent database is difficult to interpret and requires some 
critical evaluation and further research including a move from “living lab”/field-based 
approach to biomarker and cardiac function research into a more controlled laboratory 
environment (Shave et al., 2012).    
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We are not sure of the mechanism(s) for, or the long-term clinical consequence of 
exercise-induced cTn or NT-proBNP release.  Whether this represents reversible damage 
or dysfunction to the heart or some minor form of irreversible insult is important to 
determine. On-going research is needed as to why, when and how cardiac biomarkers 
become elevated during and after acute exercise bouts. Indeed, without better 
understanding of this phenomenon there will be continued confusion and concern when 
advising athletes engaging in different exercise or training strategies. In beginning to 
understand the reversible/irreversible nature of these insults “clinically-relevant” 
processes such as ischaemia has been proposed as a potential mechanism in past cardiac 
biomarker studies but too date there is no available empirical evidence to implicate 
ischaemia. 
 
Consequently, the primary focus of this thesis is to employ the high sensitivity (hs) cTnI 
assay, which has the ability to identify lower levels of cTn compared to standard assays, 
to determine the presence of elevated cardiac biomarkers during and after moderate to 
high intensity endurance exercise in healthy individuals in a controlled laboratory setting.  
A secondary focus it to begin to explore a potential mechanistic role for ischaemia in the 
appearance of cardiac biomarkers during and after exercise in human competing high 
intensity and high volume exercise. 
 
1.2. Thesis Overview  
Initially, this thesis will provide a review of relevant past literature in relation to cardiac 
biomarker and functional responses to acute endurance exercise.  Four empirical studies 
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are then described.  In study one we describe the response of cTnI, using the new hs-cTnI, 
assay, as well as NT-proBNP to 2 hour of treadmill running exercise in healthy subjects 
within a laboratory-controlled environment.  Study 2 is linked to study 1 in that it 
specifically addresses the issue of the repeatability of exercise-induced cardiac biomarker 
release as the same participants completed two further (identical) 2 hr treadmill exercise 
bouts undertaken 1 and 12 weeks after the first bout (week 0). 
 
Study 3 and 4 both address the potential role of ischaemia in exercise-induced cardiac 
biomarker release.   In an attempt to increase the intensity of exercise, participants in 
study 3 undertook two 1-hour cycle time trials in a controlled laboratory environment 
with biomarkers and cardiac function assessed during early recovery.  The potential 
mediating role of ischaemia was addressed by the application of remote ischemic 
preconditioning (RIPC) before one trial.  This was then compared to a SHAM 
intervention. The final study employed the same research design, outcome measures and 
RIPC intervention but employed a repeated 160 km cycle ride as the exercise exposure.   
 
This group of studies will provide new insight into exercise-induced cardiac biomarker 
release, its repeatability, its association with ischaemia and its link to cardiac function.  
We will add new knowledge to the debate about whether exercise-induced cardiac 
biomarker release reflects reversible or irreversible damage/decline to cardiomyocytes. 
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Chapter 2:  
Review of the literature  
2.1. Definition and History of Cardiac Biomarkers 
Historically biomarkers are normally easy-to-access (often blood borne) markers that 
attempt to reflect, as accurately as possible, patho-physiological processes in the body.  
Cardiac biomarkers “represent” events in the heart and central cardiovascular system and 
are normally parameters or indices that are easier to measure or access than some 
complex cellular or sub-cellular process of importance.  Cardiac biomarkers tend to 
reflect processes such as damage, dysfunction and/or elevated risk of a pathological 
event.  Biomarkers as measures of cardiovascular health status or future risk are, 
therefore, highly popular and prevalent in medical science. 
 
One of the earliest cardiac biomarkers assumed to reflect the cardiomyocyte damage 
associated with pathological processes, such as heart attacks, was creatine kinase (CK-
MB; Apple et al., 1994). Creatine kinase (CK) is an enzyme involved in the synthesis of 
ATP from phosphocreatine, anaerobically, when energy is required rapidly in large 
quantities such as during very short bursts of high intensity exercise.  CK is a dimeric 
molecule composed of M and/or B subunits. These two proteins can form into 3 different 
isozymes:  CK-MM, CK-MB, and CK-BB. CK-BB and CK-MM are located in brain and 
skeletal muscle, respectively. The detection of cardiac damage and dysfunction was 
focussed on CK-MB and early exercise studies employed this biomarker.  Significant 
elevations in CK-MB, above reference levels and into the range suggestive of myocardial 
damage, were observed after marathon running (Ohman et al., 1982; Cummins et al., 
1987).  An important requirement of any cardiac biomarker is a high specificity and 
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concentration within cardiomyocytes (Kemp et al., 2004).  Disappointingly, there has 
been evidence to show that CK-MB is also present within skeletal muscle and it is 
possible the exercise-related skeletal muscle damage can elevate CK-MB, which would 
reflect a “false-positive” for cardiac damage (Schneider et al., 1995; Collinson et al., 
2001). As a consequence, other cardiac biomarkers have been developed over the last 30 
years. 
 
Cardiac troponins are part of the thin filaments within the contractile protein of the 
cardiomyocyte that have defined roles in the calcium-mediated regulation of muscle 
contractions.  Two of the three cTn complex (cTnI and cTnC) are only found within the 
myocardium (there are small amounts of cTnT in other tissues) and thus cross-reactivity 
with skeletal muscle is less of a concern.  Despite this the first generation cTnT assay 
used a bovine antibody and there was some evidence of cross-reactivity with skeletal 
myocytes, making it unclear if the origin of cTnT was from skeletal muscle, cardiac 
muscle or both (Collinson et al., 2003).  The 2nd and 3rd generation cTnT assays used 
recombinant human antibodies in the assay and this significantly improved cardiac 
specificity (Collinson et al., 2003).  Originally, cTnT was preferred over cTnI as there 
was, commercially, only one well-defined cTnT assay (Roche) but there were multiple 
cTnI platforms and assays making vendor-based differences an issue for data 
interpretation.  
 
Because of the cardiac-specificity of more recent cTn assays any elevation was thought to 
reflect cardiomyocyte damage and thus became important in clinical decision making 
(Ford et al., 1999).  In a clinical setting, it is speculated that the early release of cTn is 
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from the cytosolic pool followed by a persistent release from the structural bound protein 
pool of the cardiomyocyte as the tissue breakdowns during apoptosis/necrosis.  Release of 
cTn from the structural pool is synonymous with irreversible damage whereas release 
form the cytosolic pool could reflect reversible cardiomyocyte insults (Jeffe & Wu, 
2011).  
 
The latest development in cTn assays has been the “high sensitivity” assays for both cTnT 
and cTnI (hs-cTn - Abbott Diagnostics, Chicago, IL, USA; Elecys, Roche Diagnostics 
GmbH, Mannheim Germany).  The rationale for the development of high sensitivity 
assays was that the detection limit and the 99th percentile of normal population data with 
the original assays were largely the same.  This meant any detectable cTn value was 
likely clinically significant and prognostic. Indeed the magnitude of cTn release was 
significantly correlated with tissue damage, scar size and prognosis (Collinson et al., 
2006).  With a relatively high detection threshold there was some concern that the “old “ 
assays were under-reporting low levels of cTn release and those low levels of 
cardiomyocyte damage may be of some clinical relevance.  The hs-assays also has the 
potential to uncover “resting” levels of circulating cTn which was not observed with older 
assays and whose clinical value is unknown. The new hs-cTn assay can differentiate cTn 
levels approximately 100 fold lower than the standard assays. (Westwood et al., 
2015)William et al (2018) stated that even minor hs-cTn changes can have significant 
clinical impact at a patient level and, therefore, the ability to access lower levels of hs-
cTn is likely to augment the frequency of positive or meaningful results.  The challenge is 
to distinguish false reassurance or alarm of myocardial damage. Frankenstain et al (2011) 
monitored reference values for cTn in 20 healthy participants at 1 ,2 ,3, and 4 h and then 
1, 2 ,3 , and 4 weeks after initial assessment. They concluded that in order to interpret hs-
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cTn data over serial measurements the data from this study related to biological variation 
is highly important.  Biol0gical variation was, however, quite low over this timeframe. It 
would seem pertinent that this assay is adopted in exercise settings where the 
quantification of baseline data and low magnitude cTn responses to exercise are common.  
Consequently, in the empirical data chapters in this thesis we employ hs-cTn assays.  
 
B-type natriuretic peptide (BNP) is a 32 amino acid polypeptide that is secreted with N-
terminal pro-brain natriuretic peptide (NT-proBNP) by the left and right ventricular 
cardiomyocytes in response to volume or pressure overload when the “wall”, or more 
specifically the cardiomyocytes, are stretched (Weber et al., 2005).  Thus increased levels 
of BNP (or NT-proBNP) reflects an increase in myocardial wall stress and has been 
widely used as a biomarker to monitor cardiac disease progression, risk or status in cases 
where overload of the heart is likely to occur; such as in congestive heart failure (Foote et 
al., 2004; Scharhag et al., 2008).  NT-proBNP has emerged as an excellent diagnostic 
biomarker in many heart diseases but is most commonly used in heart failure as a routine 
part of diagnosis, risk assessment and treatment (Gustafsson et al., 2005).  A systematic 
review of clinical studies by Hill (2014) determined the diagnostic and prognostic 
performance of NT-proBNP (76 articles) reflected excellent sensitivity in the diagnosis of 
heart failure.  The clinical cut-off point for NT-proBNP was set at 0.45 ng/mL for patients 
<50 year olds and 0.90 ng/mL for 50-75 years old. Most studies related to prolonged 
exercise linked to elevated NT-proBNP have completed a single measurement at baseline 
and this does not explore the natural or biological variation that exists with baseline 
concentrations of NT-proBNP (Zile et al 2016).  It has been suggested that repeated 
biomarker measurements may be required to reflect more accurately the dynamic and 
progressive nature of the underlying pathophysiological processes, such as mechanical 
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overload, cardiac fibrosis, and inflammation, and therefore may be more suitable for 
additional prognostic information (Meijers et al., (2017).  Despite this, the increases in 
NT-proBNP with ultra-endurance exercise are generally much greater than biological 
variation in resting values.  
 
As well as having a clear clinical role in cardiovascular disease detection and prediction, 
it has become apparent that the imposition of exercise has been show to result in a 
transient elevation of both cTn and NT-proBNP in healthy athletes (Scharhag et al., 2005; 
Scharhag et al., 2008; Nie et al., 2010; Shave et al., 2010). Many issues related to this 
phenomenon remain unclear.  The presence of biomarker release with different 
populations, undertaking different exercise tasks is described poorly.  Likewise the 
consistency of the exercise response of both biomarkers, the clinical significance (if any) 
of these elevations and the processes or mechanism(s) that underpin the changes in these 
biomarkers with exercise is not known.  These issues drive the focus and general rationale 
of this thesis.  
 
2.2. Cardiac Troponin (cTn) and Exercise 
Descriptive evidence of exercise induced cTn biomarker elevation has been presented in 
many empirical studies in the last 30 years including work from our own research group 
and/or collaborators (Shave el al., 2002; George et al., 2005; Whyte et al., 2005; 
Middleton et al., 2006; Middleton et al., 2008; Legaz-Arrese et al., 2015).  Despite 
widespread descriptive evidence of cTn presence in the circulation after acute exercise 
bouts there is evidence of a significant level of between-subject and between-study 
variability in biomarker response.  For example, Mair et al., (1992), who used 2nd 
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generation cTnT assay after a 230 km cycle ride, noted an elevated value in only 1 out of 
28 participants. Bonetti et al., (1996), who employed a 2nd generation cTnT assay after a 
stage of the Tour d’Italia, reported elevated biomarker levels in 5 out of 28 cyclists. Mair 
et al., (1997), again using 2nd generation assays, reported no elevation in cTnT or cTnI 
after a 67 km Alpine marathon using 2nd generation assays.  Alternatively, Scharhag et 
al., (2005), who examined cTnT and cTnI in 105 endurance athletes after a marathon 
(n=46), 100 km ultra-marathon (n=14) or a long distance mountain bike ride (n=45), 
noted that cTnI was elevated in 78% of athletes whereas cTnT exceeded its URL in 47% 
of athletes. Finally, Fortescue et al., (2007), in the largest single study to date, observed a 
cTn elevation post-marathon running in 328 out of 482 runners.  Clearly, there are a set of 
research design, personal, exercise or environmental circumstances that contribute to such 
individual heterogeneity in biomarker response to specific exercise stimuli.  
 
Narrative reviews have suggested that the variability in the cTn response to exercise 
likely reflects inconsistency within the research designs and participants employed in 
multiple small studies (Shave et al., 2010).  Specifically, variation in subject age, sex, 
fitness, exercise modality, intensity, duration, number of blood draws and type of cTn 
assay have all lead to diverse data and some confusion (Shave et al., 2010).   Most of the 
original investigations have used different assay types (1 st, 2nd, 3rd and 4th generation or 
hs-cTn assay) and employed small sample sizes in a vast array of settings (laboratory, 
field, competitive, non-competitive, different environmental stresses), participants (males, 
females, young, old, athletes, and charity runners) and exercise intensities (walking, 
jogging, race pace and sprinting).  What is of interest is that few of these factors have 
been independently studied by controlled, manipulated designs to address the importance 
of individual factors or the synergy between issues. Consequently drawing this evidence 
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together has been problematic.  Despite this, both narrative and structured reviews have 
attempted to produce an overview of cTn release associated with exercise (Scharhag et 
al., 2005; Shave et al., 2007).  
 
As a way to summarise the variety of disparate data from smaller individual studies, 
Shave et al., (2007) completed a meta-analysis that assessed 1120 participants from 26 
relevant acute-exercise studies.  Table 2.1 documents details from the individual studies 
and heterogeneity in outcome is noticeable.  The key finding from the meta-analysis was 
that the “event rate”, the likelihood of cTnT being detectable (above URL of 0.01µg/1), 
after acute exercise, was 47%.  Running events resulted in a slightly higher event rate of 
52% of cTnT compared to cycling of only 27% (Table 2.1). 
 14 
 
Table 2.1. Participants with significant cTn elevation post exercise (adapted from Shave, 2007) 
STUDY NAME EXERCISE  
MODE 
GENDER  
(% MALES) 
MEAN  
AGE  
(YEARS) 
MEAN  
BODY  
MASS  
(KG) 
MEAN  
DURATION  
(MIN) 
EVENT  
RATE 
LOWER  
LIMIT 
UPPER 
LIMIT 
DATA 
Shave et al., (2004) cycle 100 28 74.9 254 0.06 0.00 0.50 1/9 
Neumayr et al., (2002) cycle 100 37 72.5 1342 0.06 0.01 0.34 1/16 
Shave et al., (2004) cycle 100 34 77.7 126 0.13 0.02 0.54 1/8 
Dawson et al., (2005) cycle 100 31 78.2 240 0.13 0.03 0.39 2/16 
Neumayr et al., (2005) cycle 100 34 70.4 550 0.45 0.28 0.63 13/29 
Scharhag et al., (2005) cycle 93 36 74.0 360 0.51 0.37 0.65 23/45 
George et al., (2005)  run 100 21 75.9 85 0.03 0.00 0.30 1/20 
Shave et al., (2002) run 100 29 77.0 30 0.06 0.00 0.50 1/9 
Scharhag et al., (2005) run 71 44 69.0 607 0.21 0.07 0.49 3/14 
Shave et al., (2005)  run 86 44 71.5 613 0.35 0.22 0.50 15/43 
Middleton et al., (2005) run 100 33 70.4 139 0.36 0.14 0.66 4/11 
Shave et al., (2003) run 0 44 57.3 374 0.43 0.14 0.77 3/7 
Shave et al., (2002) run 100 33 77.7 301 0.44 0.18 0.75 4/9 
Scharhag et al., (2005) run 87 40 73.0 238 0.52 0.38 0.66 24/46 
Apple et al., (2002)  run 58 38 * 289 0.53 0.31 0.73 10/19 
Whyte et al., (2005)  run 17 35 75.9 245 0.62 0.48 0.74 32/52 
Neilan et al., (2006)  run 68 41 71.7 285 0.63 0.51 0.74 38/60 
Middleton et al., (2006)  run 93 29 75.9 212 0.64 0.38 0.84 9/14 
Fortescu et al., (2007) run 67 39 * * 0.68 0.64 0.72 328/482 
George et al., (2005) run 79 33 76.0 256 0.72 0.54 0.86 21/29 
George et al., (2004) run 89 36 81.2 256 0.74 0.58 0.86 26/35 
Rifai et al., (1999) triathlon 0 43 56.0 715 0.17 0.04 0.48 2/12 
Shave et al., (2004) triathlon 100 41 74.0 506 0.50 0.32 0.68 13/26 
Cleave et al., (2001)  Triathlon * * * * 0.56 0.43 0.67 35/63 
Tulloh et al., (2006) triathlon 95 38 * 686 0.84 0.69 0.93 32/38 
 
*Data that were unavailable, gender according to the percentage of men in the study sample, sample size (total) 
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The explanation for running having a higher event rate was not clear although post-hoc 
analysis also suggested that the longer the event the slightly lower the event rate  which 
likely relates to exercise intensity (specifically higher event rates were noted for 
marathons compared to longer running events). Whilst informative this meta-analysis 
did not quantify the precise characteristics of exercise that promote cTn release and/or 
contribute to the understanding of the significance (clinical) or mechanisms.  This 
work has acted as a general stimulus for on-going study and analysis. Specifically, this 
analysis and other commentary’s raised a couple of key issues that limited data 
interpretation; (1) single post exercise blood samples (normally immediately after 
exercise) and (2) variable assay use with limited data using new high sensitivity 
techniques.   
 
In addressing point (1) Middleton et al., (2007) studied 8 runners who completed a 
marathon distance run (self-selected pace) on a treadmill.  This laboratory-controlled 
approach allowed blood draws every 30 min (during exercise) and at multiple time 
points in recovery, (up to 24 hr post run completion).  Employing a 3rd generation 
assay for cTnT, uniquely this biomarker was elevated in all athletes during exercise 
and in all but one participant at some (but varied) point during recovery (Figure 2.1). 
There was a moderate quantitative release of cTnT (range 0.02 to 0.04 µg/L) during the 
first 60 minutes of treadmill running at marathon pace. The data suggested a biphasic 
response, which may be interpreted as similar to a clinical release, although the 
absolute levels and rapid turnover would suggest a non-clinical response.  This study 
provided stark evidence of the limitation of many field-based studies that only used pre 
and a single post-exercise biomarker assessment point.   A clear consequence of this 
study for the work contained in this thesis is that multiple blood draws should be 
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incorporated into any study design, controlled-laboratory or field-based, to get more 
accurate insights into cardiac biomarker turnover during and after strenuous exercise.  
 
Figure 2.1. Individual cTnT Release During and After Completion of a Lab-based 
Marathon (Middleton et al., 2007). 
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In respect to point (2) Vilela et al., (2014) recently reviewed the available evidence of 
hs-cTn release in sport and exercise settings.  As a newer biomarker the evidence-base 
is much smaller, but this review and meta-analysis was still timely for on-going work 
(Table 2.2). Vilela et al., (2014) reported data for a total of 479 participants performing 
strenuous exercise in studies between 2009 and 2013.  The main outcome was a 
positive response rate for cTn appearance in two-thirds (69.8%) of the participants in 
the review, irrespective of the exercise mode, intensity and volume undertaken.  
Further Vilela et al., (2014) noted that (a) baseline values of hs-cTnI were relatively 
low, (b) hs-cTnI increased during exercise to early recovery, (c) peaked at 3 – 4 hours 
post exercise, and (d) recovered considerably by 24 hr post-exercise.  Evidence of the 
combined use of the new hs-cTn assay with multiple blood samples is to be 
commended. Vilela et al., (2014) concluded that it is likely that cTn release with 
exercise reflected a reversible insult to cardiomyocytes but could not provide insight 
into mechanism(s) of release.  Further, most work to date reported by Vilela et al., 
(2014) consisted of studies of athletes performing very high exercise volumes and thus 
placing considerable hemodynamic demands upon the heart.  A consequence of this is 
that there is a clear rationale to assess hs-cTn turnover during and post exercise in less 
well-trained individuals completing less strenuous exercise, whilst employing multiple 
blood draws.  This is the focus of the first study in this thesis.   
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Table 2.2. Studies employing hs-cTn assays to assess the cardiac biomarker 
response to strenuous exercise (adapted from Vilela et al., 2014) 
STUDY 
NAME 
MODE DESIGN  SAMPLE DATA 
Mingels 
et al., 
(2009 
Running 
(marathon)  
Assessed by highly 
sensitive cardiac 
troponin T and 
commercial cardiac 
troponin T and I 
assays pre and post 
exercise 
85 The runners had cTnT concentrations 
greater than the 86% 99th percentile with 
the hs-cTnT assay compared to 45% using 
the Roche 4th generation cTnT assay.  
Indicating detection depends highly on an 
assay's limit of detection. 
Mingels 
et al., 
(2010) 
5,  15, 21 and 
42 km  
) using hs-cTnT 
assay pre and post 
exercise.  
297 The distance covered was related to the 
elevation of cTnT post exercise.  86%, 
median 0.030 µg/L The use of hs-cTnT is a 
predictor of cTnT post exercise when 
using hs-cTnT assay after the marathon.  
Saravia et 
al., (2010) 
Running 
(marathon) 
Comparison 
between hs-cTnT 
and 4th generation 
cTnT assay during 
Berlin marathon 
2006 pre and post 
exercise.   
78 Post-race fourth generation was 
significant in 43%, hs-cTnT was positive in 
all runners. 
Scherr et 
al., (2011) 
Running 
(marathon) 
0, 24 and 72 h post 
marathon  
102 hs-cTnT peaked immediately post 
exercise and showed the rapid removal 
often seen during exercise. (values 
returned to normal levels within 72 h).     
Lippi et 
al., (2012) 
Running (60 
km ultra-
marathon 
Before and 
immediately after 
race 
15 Post-race assay was above URL in 12 
participants (80%; P < 0.001) using both 
the hs-cTnI.  
Tian et 
al., (2012) 
Running (90 
min  treadmill 
run, 95% 
ventilatory 
threshold) 
0, and at 1, 2, 3, 4, 
5, 6, and 24 h post-
exercise 
 
13 Peak hs-cTnT occurred at 3–4 h post 
exercise in all runners, but was 
substantially higher (P < 0.05) in 
adolescents [median (range): 211.0 
(11.2–794.5) ng/l] compared with adults 
[median (range): 19.1 (9.7–305.6) ng/l]. 
Peak hs-cTnT was followed by a rapid 
decrease in both groups, although 
adolescent data had not returned to 
baseline at 24 h 
 
 
2.3. NT-proBNP and Exercise  
The significance of elevated NT-proBNP during exercise is poorly understood, despite 
the fact there is a growing database detailing the NT-proBNP response to different 
exercise bouts (Shave et al., 2007; Table 2.3). For example, Vidotto et al., (2005) 
assessed NT-proBNP levels before and after a half marathon with little evidence that 
running a half-marathon altered this cardiac biomarker. Conversely, Scharhag et al., 
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(2008) assessed NT-proBNP responses in a large cohort (n=105) healthy athletes with 
samples taken before, 15 minutes, and 3 hours after a marathon (n = 46), a 100-km run 
(n = 14), and a mountain bike marathon (n = 45). NT-proBNP increased in all 3 events 
(P < .001) with the highest increase in the 100-km runners (median increase 200 ng/L; 
25th/75th percentile 115/770 ng/L), which differed from the increase in the marathon 
(97 ng/L; 36/254 ng/L) or the mountain bike marathon (78 ng/L; 37/196 ng/L) (P < 
.01). Further, 81 of 105 athletes exceeded the URL of NT-proBNP (males/females 
88:153 ng/L) after exercise.  This suggests a role for duration over exercise intensity 
(and thus accumulated hemodynamic stress) in the exercise-related rise in NT-proBNP. 
 
Recent studies have attempted to interrogate issues that may mediate NT-proBNP 
responses to exercise. Legaz-Arrese et al., (2015) assessed the NT-proBNP response to 
high intensity rowing.   In 18 elite and 14 amateur rowers undertaking a 30 min 
maximal rowing test NT-proBNP rose in all subjects and recovered to baseline by 24 hr 
post-exercise. There were no significant differences in baseline and peak post-exercise 
NT-proBNP between groups.  This suggests that athlete status does not mediate NT-
proBNP responses to exercise.  A study by Sahlen et al., (2008) demonstrated a 
correlation between high baseline levels of NT-proBNP and the amount released 
during prolong exercise. The participants were 43 senior endurance runners, > 55 years 
(mean age 61 + 4), who completed a 30 km cross-country race.  Whether these results 
are a consequence of the use of “mature” athletes has yet to be determined.  Fu et al., 
(2010) studied adolescent runners (mean age 16.5 + 1.6 years, N=17), before, 
immediately after and 4 hours after endurance exercise. 29% of runners had baseline 
NT-proBNP above URL and these runners had greater absolute increase in NT-proBNP 
post exercise.  Fu et al., (2010) proposed that the higher levels of NT-proBNP may be 
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an important part of the myocardium’s transition from childhood to maturity.  Again 
more work is needed to test this specific point, possibly with a long-term research 
design as athlete’s age and mature. 
 
A range of studies has demonstrated, like cTn, inconsistencies in the NT-proBNP 
response to exercise.  Again, similar limitations must be noted including many studies 
adopting an uncontrolled “field” exercise exposure and limited recovery blood 
samples.  Reduced numbers of post-exercise blood samples promotes the possibility of 
grossly underestimating any peak exercise response (Scott et al., 2009).  Whilst 
narrative reviews have attempted to inform and produce an overview of NT-proBNP 
responses to prolonged exercise (Shave et al., 2005; Scharhag et al., 2008) there is still 
a requirement for descriptive research in controlled exercise settings and in different 
participant groups, whilst employing multiple blood draws.  Consequently, in this 
thesis we will assess NT-proBNP alongside hs-cTn in a range of exercise settings.  
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Table 2.3. Studies employing NT-proBNP assays to assess the cardiac biomarker 
response to endurance exercise (adapted from Vilela et al., 2014) 
 
 
 
2.4. Repeatability of Cardiac Biomarker Response to Exercise  
There is substantive evidence to show that single bouts of exercise can stimulate the 
appearance of cardiac biomarkers of damage and dysfunction in the blood stream 
(Shave et al., 2007; Shave et al., 2010). In considering the clinical implications and 
importance of this biomarker phenomenon there has been some interest in determining 
STUDY NAME EXERCISE  
MODE 
DESIGN SAMPLE DATA 
Legaz-Arrese 
et al., (2015) 
High intensity 
rowing (30 min)  
Blood draws pre-test 
and 5 min, 1,3,6,12 and 
24 h  
Elite ( n = 
18) 
Novice (n 
= 14) 
Biomarker rose in all 
subjects and recovered to 
baseline by 24 hr post-
exercise.  Athletic status did 
not mediate NT-proBNP 
responses to exercise 
Salvagno et 
al., (2015) 
Running, 
ultramarathon (60 
km) 
Pre and immediately 
post-run samples 
n = 18 Significant increase after the 
run for NT-proBNP, 5/18 
(28%) values     > 125 ng/L. 
 
Fu et al., 
(2010) 
strenuous running 
for 21 km 
Blood draws pre, 0 and 
4h post run 
n =17 
(adolesce
nts) 
NT-proBNP increased by 50% 
post exercise (123 + 51 vs. 
193 + ng/L.  High levels may 
indicate myocardium 
growth. transition 
Sahlén et al., 
(2008) 
Running, 30 km 
cross country race  
Pre and immediately 
post exercise blood 
draws  
n = 43> 55 
yr old 
A correlation between high 
baseline levels of NT-proBNP 
and the amount released 
during prolong exercise. This 
age group may have an 
adverse effect to exercise. 
Scharhag et 
al., (2008) 
Mountain bike, 
100 km run and 
marathon 
Blood samples 15 min 
and 3 hours post 
exercise 
bike (n = 
45) 
run (n = 
14) 
The 100km run had the 
highest increase of NT-
proBNP above URL, 200ng/L. 
81 of 105 athletes exceeded 
the URL 
Lippi et al., 
(2008) 
Running half 
marathon (21 km) 
Blood samples 0, 3, 6 
and 24 hr post-exercise 
n = 17 No participant exceeded 
URL.   Cut off used to define 
URL 194 ng/L. 0/17   
Vidotto et al., 
(2005) 
Runners, half 
marathon (21 km) 
Blood samples were 
taken pre and 20 min, 2 
hr post-exercise 
Male (n = 
12) 
female (n 
= 13) 
Running 21 km altered 
cardiac biomarker elevation.  
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if this is a consistent or repeatable phenomenon.  The basic standpoint is that if this 
biomarker response is repeatable, predictable and therefore by association an 
obligatory response to exercise stress, this likely means that it is a physiological 
phenomenon. 
 
To date only a limited number of studies have identified if the exercise-related 
appearance of evidence of cTn and/or NT-proBNP is a highly repeatable phenomenon 
(Middleton et al., 2007; Sahlen et al., 2008;Tian et al., 2014; Wedin & Henriksson 
2015).  Sahlen et al., (2008) assessed the repeatability of the hs-cTnT and NT-pro-BNP 
response in mature athletes pre and immediately after a 30 km cross-country race with 
3 years between each race.  The correlation coefficients for the biomarkers between the 
two races were r = 0.82 for NT-proBNP and 0.84 (Spearman’s rho, both p <0.001).  
This suggests some level of consistency of response although the intervening 3 years 
may have led to substantial changes in individual fitness and health that may challenge 
the true nature of the repeatability of this phenomenon.   
 
Wedin & Henriksson (2015), expanded the research area by using elite, intermittent 
high-intensity exercise.  Participants (n=16) with a median age of 19 years,  completed 
two matches of Scandinavian floorball with 3 months between the two games.  Blood 
was analysed at pre, immediately after and 2 hours post games. The authors noted at 2 
h post-match moderate reproducibility for elevated hs-cTnT (ICC = 0.368).  
Middleton et al., (2007) and Tian et al., (2014) employed a much more constrained 
time period for their repeated exercise bouts which likely exerted more control over the 
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test design and data collection. Middleton et al., (2007) assessed three repeated 15-mile 
hill runs over three consecutive days with blood draws taken pre, 0, 1, 20 h after each 
bout of exercise.  cTnT was elevated above detection levels in 4 runners 1 h after the 
first bout of hill running (0.013 – 0.125µg.L-1) but no detectable elevations were 
observed after the other 2 bouts of running in the same participants. This does not 
support the concept of a repeatable phenomenon over a short time frame. Tian et al., 
(2014) employed a controlled laboratory based setting for their study, with blood draws 
taken at 0 and 3 h post-exercise, with identical 90 min treadmill runs separated by 3 
weeks. A significant elevation in hs-cTnT was noted after both trials but a clear 
“blunting” in the magnitude of response was observed after the second bout of 
exercise.  The authors suggested some sort of “learning effect” could have caused the 
lower hs-cTnT response in Trial 2.  Given the timeframes involved and the reduced 
cTn response in second exercise bout, this data could reflect a “repeat-bout” effect.  
This draws parallels with work associated with skeletal muscle fatigue and damage and 
the release of the CK-MM biomarker after repeat bouts of exercise (normally 
eccentric) where skeletal muscle damage is assumed. Although descriptive in nature, 
some researchers have speculated that what is happening to the cardiac muscle is akin 
to the adaptive response to delayed onset muscle soreness (DOMS) after damaging 
exercise in skeletal muscle.  The “repeat bout” effect is where a single eccentric 
exercise bout that results in skeletal muscle damage then imparts a “refractory period” 
and reduced damage occurs in subsequent and similar exercise challenges in the same 
people and same muscle groups (Cheung et al., 2003).  This requires further 
substantiation with cardiac biomarkers. The general lack of consistency in the data 
assessing the repeatability of the cardiac biomarker response to exercise drives the 
rationale for the second study in this thesis using active participants in a laboratory 
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setting with more experimental control whilst assessing both hs-cTn and NT-proBNP.  
The potential for a repeat bout effect when exercise is repeated in a short time frame 
also drives the rationale to have three identical exercise tests with the first two bouts 
separated by a week and the final bout 12 weeks later that allows repeatability and the 
repeat bout effect to be assessed.   
 
2.5. Clinical Consequences and Potential Mechanisms of Cardiac Biomarker 
Release  
Despite continuing debate in relation to the exact prevalence of “positive” cTn and NT-
proBNP responses during, and after prolonged exercise, the simple presence of this 
response has raised important concerns for athletes, coaches, physicians and 
researchers alike (George et al., 2012).  Clinically, significant elevations in cTn’s and 
NT-proBNP could be indicative of the pathological processes associated with disease 
or injury of the myocardium.  Exemplars of athletes suffering an acute cardiac arrest 
during the high stress environment of sports performance are, thankfully, rare. Despite 
this when such events happen it is very shocking and often generates significant media 
attention. For the clinician attending a sport event, or even an Accident and Emergency 
Department receiving athletes post-event, they must by confident in their differential 
diagnosis.  If the presence of cardiac biomarkers after exercise reflects a pathological 
process this could have negative cardiovascular health consequences, which must be 
assessed quickly, and accurately (Whyte, 2007).  
 
The appearance of cardiac biomarkers in cases of acute cardiac syndromes and chronic 
heart failure are well documented.  Acute coronary syndrome generally have a biphasic 
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cTn release, with an initial cTn appearance approximately 2 h after the event followed 
by extended release that can last for many days (Collinson et al., 2003).  Despite this 
we know biomarker release can occur outside of “frank coronary disease”.  There are 
ample case studies of cTn elevation in (for example) tsako-tsubosyndrome (also known 
as stress cardiomyopathy)  or ventricular tachycardia (high heart rate) where there is no 
documented coronary artery disease and the long term cardiomyocyte damage is likely 
negligible. Consequently, the exercise response may be clinically irrelevant and 
reversible and simply reflective of a heightened cardiac workload.    
 
Despite the standpoint noted above there is still very little data (especially in humans) 
as to what potential mechanisms are at play in this phenomenon.  A number of 
scientists have speculated that exercise-related cardiac biomarker release reflects 
passive diffusion cross the cell membrane due to an increase in permeability, similar to 
that seen with the adaptation process in skeletal muscle hypertrophy (Neymayr et al., 
2004).  This might suggest a reversible mechanism that is assisting in cardiac remodelling 
(McNeil et al., 1992; Scharhag et al., 2006; Shave, 2010).  Although the mechanical 
process of heart remodelling remains unclear, Reactive oxygen species (ROS) have been 
linked to both cardiac damage and cardiac remodelling (Dennis et al., 2014).  Reactive 
oxygen species are a group of highly reactive molecules, which have the potential to 
modulate several biological processes as well as cause tissue damage and dysfunction. 
Their effects can be beneficial or deleterious, depending on the concentrations produced 
and the site of production. For example, Schiattarella (2017) indicated that there is a 
positive correlation between specific markers of oxidative stress and cardiac remodelling 
in patients with coronary disease. 
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Another speculative idea for the cause of cTn elevation with exercise is the release of 
integrins caused by the increased myocardial stretch during prolonged exercise (Koller , 
2009). Integrins are transmembrane receptors that assist the passage of cTn molecules 
out of the cardiomyocytes (Hessel et al., 2008).  Hessel et al., (2008) hypothesised that 
the stretch-related process stimulates the release of cTnT & cTnI with the help of 
integrins. Despite this speculation there is no empirical data assessing the role of any 
potential mechanisms in cardiac biomarker release with exercise in humans (Dawson et 
al., 2003; Viela et al., 2014). 
 
Another potential mechanism for cTn or NT-proBNP release with exercise is excessive 
right ventricular overload.  Evolving research has expanded our understanding of how 
prolonged exercise, such as marathon running and ultra-endurance events, places a 
disproportionate afterload on the RV (Shave et al., 2008). Evidence indicates a moderate 
correlation between a reduction in RV ejection fraction and increase in cTn and NT-
proBNP after exercise, but with little or no relation to changes in LV function (La Gerche 
et al., (2014).   Research data suggests that a greater relative increase in pulmonary 
afterload with exercise places the RV under a disproportionate increase in stress during 
prolonged exercise leading to potential overload and stress/injury in the RV   
 
2.5.1. Ischaemia and Cardiac Biomarker Appearance 
In a clinical setting one of the mechanisms that underpins cTn elevation is 
cardiomyocyte ischaemia that leads to a cascade of events resulting in cell death and 
biomarker release (Shave et al., 2010).  It has been speculated that “sub-clinical” 
ischaemia may contribute to exercise-related biomarker release (Dawson et al., 2003) 
although this has not been directly tested as a hypothesis in a human-exercise setting.  
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Recently the development of ischemic preconditioning has presented an opportunity to 
indirectly evaluate the role of ischaemia in exercise-related cardiac biomarker 
appearance. Ischemic preconditioning (IPC) developed from the pioneering work by 
Murry et al., (1986) when dogs were exposed to 4 x 5 minute of coronary artery 
occlusions, too brief in themselves to cause myocyte death, interspersed with five-
minutes of reperfusion.  This was compared to a control period with no meaningful 
IPC.  An ischemic event akin to a cardiac arrest was then induced in all animals.  The 
results of the study demonstrated that; (1) dogs that received the IPC had a 75% 
reduction in ischaemia in the secondary ischemic insult, and (2) the dogs that received 
IPC had a much smaller infarct size.  
 
Since the early 1990s there have been a range of clinical and physiological studies 
assessing the value and utility of IPC.  A key development from the perspective of 
clinical application has been the use of remote ischemic preconditioning (RIPC) where 
the ischemic stimulus is presented in a different artery (e.g. a limb) to that where the 
assessment of effect of the ischemic preconditioning is still measured (i.e. the heart).  
Przyklenk et al., (1994) pioneered the development of RIPC by showing that brief 
occlusion of the circumflex artery rendered the myocardium served by this artery as 
resistant to further incidents of ischaemia.  More importantly, canines underwent 4 x 5 
circumflex artery occlusion with 5 minutes of reperfusion, then 1 hour of sustained left 
anterior descending coronary artery occlusion and 4.5 hours of reperfusion. Their study 
showed that the IPC to the circumflex artery provided some protection against 
myocardial damage after left anterior descending artery occlusion. This implied that 
the protection from ischaemia/reperfusion can occur at a point distant to the site of 
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IPC. Indeed, further studies in animals showed that even when IPC was applied to a 
major arteries in distant organs (e.g. hind limb, lower leg, kidney) the infarct size in the 
heart was still reduced and thus protection against subsequent myocardial injury was 
evident (Aon et al., 2010). The exact mechanism(s) of ischemic preconditioning 
remains obscure.   
 
As a consequence of these developments noted above Cheung et al., (2003) employed 
RIPC in a study in children undergoing repair to congenital heart defects.  Four 5-
minute cycles of RIPC were applied to produce lower limb ischaemia-reperfusion in 17 
children.  Lower cTnI release was then observed compared to the control (p=0.04) 
during surgery. The authors suggested the reduction in cTnI with surgery after RIPC 
could indicate a possible protective effect of RIPC on subsequent myocardial injury 
(see Figure 2.2).   
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Figure 2.2. Pre and post-operative levels of troponin I after the application of 
remote ischemic preconditioning (RIPC) or a control (from Cheung et al., 2006). 
 
  
 
Systematic reviews and meta-analyses have confirmed that RIPC can reduce the release 
of cTn in response to an “event”. Takagi et al., (2008) performed the first meta-
analysis on RIPC in cardiovascular surgery and included data on 184 patients.  They 
demonstrated a statistically significant reduction in cTn after RIPC relative to a control 
group/procedure.  Alreja and Bugano (2012) pooled 17 clinical trials in a systematic 
review and meta-analysis to evaluate the effect of RIPC on myocardial and renal 
injury.  Patients had lower levels of cTnT or cTnI after RIPC compared to a control 
group/trial.  Pilcher et al., (2012) produced a systematic review and meta-analysis of 
the cardioprotective effects of RIPC in open cardiac surgery in 10 studies with a total 
of 693 subjects. RIPC reduced cTn levels 12 hours after surgery compared with the 
control group.  The fixed and random effects differences were 0.35 (95% CI 0.19 to 
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0.51) and 0.53 (95% CI 0.18-0.88) which indicates changes that are reflect meaningful 
cardioprotection.  
 
Translation from clinical studies to humans performing exercise has only been 
attempted once to date (Messaoudi et al., 2013) but forms a potentially interesting and 
simple way to indirectly assess the role (if any) of ischaemia in the post-exercise 
elevation in cardiac biomarkers. The study by Messaoudi et al., (2013) measured hs-
cTnI at multiple time points (0, 1, 2 ,3 ,4 and 8 h) post 70 min of cycling at 80% of 
maximum heart rate followed by exercise at 95% of maximum heart rate until 
exhaustion.  NT-proBNP was measured 1 and 3 h post exercise. The bout of cycling 
was preceded by RIPC or a control intervention.  The key outcomes were that hs–cTnI 
significantly increased, reaching a peak after 4 h post exercise but that RIPC did not 
mediate a significant change in hs-cTnI levels after exercise.  This led the authors to 
suggest that ischaemia was unlikely to play a major role in the aetiology of cTn 
appearance after exercise of this limited magnitude.  There are a number of 
methodological issues in RIPC studies generally, and the Messaoudi et al., (2013) 
study specifically, that require consideration and standardisation in future RIPC 
studies.  For example, the time, location and repetition of procedure for pressure cuff 
placement on limbs is highly variable.  Salvador et al., (2016) completed a systematic 
review and meta-analysis on RIPC and exercise performance in 19 studies.  Many of 
the 19 studies adopted the RIPC protocol used by de Groot et al., (2010) where a 
pressure cuff was placed on both thighs and inflated for 5 minutes followed by 5-
minute reperfusion period.  The ipsilateral limb was then subjected to the same 
protocol.  This process was repeated 4 times for a total RIPC exposure of 40 minutes. 
Salvador et al., (2010) proposed at least 3 cycles of hypoxic-ischemic cycles were 
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necessary to achieve a protective response although empirical support for this is still 
required.  There is a need for the correct cuff sizes to be used to allow for complete 
arterial blood flow blockage and there is also some variation in the pressure level 
employed to prevent blood flow (Dempsey et al., 1999).  The location of the pressure 
cuff has been varied in a range of studies.  Some studies have used one cuff on one 
limb, sometimes the thigh (83%), sometimes the forearm (17%). Loukogergakis et al., 
(2007) noted a greater effect when ischemic reperfusion occurred on the thighs  with 
blood flow disruption applied alternatively to both limbs.  Salvador et al., (2010) 
speculated that the more muscle exposed to ischaemia the greater the effect and 
consequently proposed that pressure cuffs should be used bilateral (left forearm and 
right thigh, then right forearm and right thigh) rather than unilateral. Finally, most 
single blind cross-over studies have used a SHAM control to help understand the 
treatment effect.  In RIPC studies to date it has been common to simply use a very low 
blood pressure, such as 20 mmHg, well below diastolic pressure and thus not disruptive 
of blood inflow or outflow to the limb.  Whether this is an effective SHAM requires 
evidence-based data in all studies as participants may notice the difference in cuff 
pressures applied.  Despite these limitations with the use of this protocol as a 
“placebo”, no specific alternatives have been proposed or tested. 
 
These studies and technical considerations provided the primary focus, or rationale, for 
studies 3 and 4 in this thesis, applying RIPC (or SHAM) prior to repeated bouts of 
cycling in the lab (3) or the field (4).  This will provide insight into the role of 
ischaemia in the cardiac biomarker release with exercise that is currently lacking or 
controversial. 
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2.6. The Link between Cardiac Biomarker Appearance and Cardiac Functional 
Changes Post-exercise.  
 
Saltin & Stenburg (1964) were the first to describe a potential decline in intrinsic left 
ventricular (LV) contractile function as a consequence of prolonged exercise in the 
presence of unaltered haemodynamic loading.  This study prompted ongoing 
investigation into the immediate or short term effects of prolonged exercise upon 
cardiac function that continue to this day (e.g. Lord et al., 2016; Eijsvogels et al., 2017; 
Oxborough et al., 2018; Lord et al., 2018); .  Most studies have been supportive of 
these initial findings if the exercise exposure is significantly large and strenuous (see 
reviews; Shave et al., 2008; Oxborough et al., 2010).  Douglas et al., (1987) termed 
this phenomenon “cardiac fatigue” and this has been broadly adopted within recent 
literature (e.g. George et al., 2011; 2012). 
 
In their meta-analysis Middleton et al., (2006) revealed an overall post-exercise 
reduction in left ventricular ejection fraction (EF), end-systolic pressure-volume ratio 
(SBP/ESV) ratio, and peak early to atrial diastolic filling velocity ratio (E/A).  This 
suggests a transient decrease in both LV systolic function and diastolic filling as a 
consequence of undertaking acute bouts of prolonged exercise (greater than 2 hr 
duration).  Further work has also reported similar changes in the right ventricle (RV) 
after prolonged exercise (Oxborough et al., 2011; La Gerche et al., 2012; La Gerche et 
al., 2014)).   
 
A significant amount of research work in relation to “cardiac fatigue” has been 
descriptive with the aim of understanding what exercise (duration, mode etc.) and 
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participant (age, sex, fitness etc.) factors may augment the appearance of changes in 
cardiac function.  This clearly parallels work with acute exercise and the cardiac 
biomarker response. 
 
Again, as with cardiac biomarkers, an important consideration of this apparent decrease 
in LV and RV function after prolonged exercise is related to putative mechanism(s) 
(Dawson et al., 2003).  Mechanistic work is often limited in human studies, especially 
those based in the field where whole organ assessment of cardiac function via non-
invasive imaging has been the primary outcome variable. On the basis of an early case 
study (Rowe 1992) and case-series data (Siegel et al., 1984) some have postulated that 
post-exercise changes in LV function were a consequence of cardiomyocyte damage, 
somewhat akin to how cardiac function declines consequent to the ischaemia and 
cellular damage that occurs with myocardial infarction (Collinson et al., 2003).  The 
work by Rowe (1992) who reported on Sy Mah’s autopsy (an athlete who set a world 
record of 524 marathons but died of non-cardiac cause) and identified fibrosis of the 
papillary muscle with the absence of atherosclerosis. Rowe speculated the fibrosis 
could have been caused by exercise-inducted vasospasm caused by localised 
ischaemia.        
 
Consequently, the concept of exercise-induced cardiac damage (EICD) was conceived 
alongside exercise induced cardiac fatigue (EICF) and the assessment and association 
of both phenomena have been descriptively studied in parallel in recent years. Whether 
one (EICD) leads directly to the other (EICF) remains a controversial issue.  In human 
work we are limited to assessing the correlation between evidence of EICF and EICD 
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and in the vast majority of cases there has been no clear link or association.  Despite 
this, Neilan et al., (2006) reported a significant correlation between cTn elevation and 
reduced RV function. Rifai et al., (1999) using participants from the Hawaii Ironman 
triathlon associated elevated cTn with qualitatively poor echo scores.  Ohers have not 
identified a direct relationship between elevated cTn and permanent cardiac function 
(George et al., 2009; Siegel et al., 1988).  This area requires further examination due to 
differential findings in past work.   
 
The studies proposed in this thesis related to the impact of RIPC on cardiac biomarker 
appearance provide an ideal scenario for assessing the relationship between EICF and 
EICD and whether both phenomenon have a relationship to ischaemia.  Our 
understanding is still at its development phase in part due to the fact that it is 
challenging to study the structure of the human heart.  Non-invasive imaging advances 
such as novel echocardiographic techniques have helped to open up new research 
directions to help to improve our understanding of what happens to the myocardium 
during and after prolonged exercise.   This provides the specific rationale for the 
inclusion of measures of cardiac function in studies 3 and 4.. Specifically we will look 
at global measures of LV and right ventricular function as well as regional myocardial 
function using tissue Doppler assessment (George et al., 2005). 
 
2.7. Summary  
The clinical literature clearly supports the notion that injury to the myocardium (or 
cardiac dysfunction) is associated with the release of significant levels of specific 
biomarkers such as cTnI/cTnT.  Further chronic heart failure has been strongly 
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associated with high levels of circulating NT-proBNP.  In both clinical scenarios 
cardiac function is also depressed. The fact that acute bouts of prolonged strenuous 
exercise may produce similar changes in cardiac biomarkers and function is, 
superficially, counter-intuitive but supported by a substantial empirical database. 
Understanding why these phenomenon happen is important in our appreciation and 
debate of the positive and negative effects of exercise on the myocardium.  
Contradictory outcomes in some studies to date also requires on-going enquiry. 
Further, there is a need for clear policies from the extensive research in this area to 
help inform sports medical staff when working in this field with athletes who present 
with elevated cardiac biomarkers or mildly depressed cardiac function after an exercise 
bout. 
 
With the development of hs-cTn assays as well as developing novel measures of 
cardiac function it is still imperative to define what happens in different bouts of 
exercise, in different populations.  This current thesis will seek to assess the nature of 
hs-cTnT and NT-proBNP responses to acute exercise and the repeatability, or potential 
repeat bout effect, associated with this phenomenon.  Further, we wish to begin to 
explore potential mechanistic issues behind these phenomena.  Whilst, ischaemia has 
long been “touted” as a key mechanism empirical data does not yet exist in humans to 
link these issues.  
 
The proposed studies will help to inform the continuing question as to whether 
“elevation of cardiac biomarkers or a depression in cardiac function after exercise” 
represents a reversible or irreversible insult to the heart.  
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2.8. Study Hypotheses  
STUDY1: Hypothesis 1: Running for 2 hours on a motorised treadmill at moderate 
intensity will reveal a rapid turnover of cTnI, using the new high sensitivity assay, and 
NT-proBNP in moderately active adults. 
STUDY 2: Hypothesis 2a: Cardiac biomarker responses to the same exercise bout 
employed in STUDY 1, are highly repeatable after a period of 7 days between exercise 
tests in the same participants.  
STUDY 2: Hypothesis 2b: Cardiac biomarker responses to the same exercise bout 
employed in STUDY 1, and Hypothesis 2a, will be highly repeatable after a period of 
12 weeks between the first and last exercise test in the same participants.  
STUDY 3: Hypothesis 3: Exercise-related changes in cTn, NT-proBNP and cardiac 
function will be attenuated when a 1-h strenuous cycle time trial exercise is preceded 
by RIPC in comparison to a time trial proceeded by a SHAM treatment. 
STUDY 4: Hypothesis 4: Exercise-related changes in cTn, NT-proBNP and cardiac 
function will be attenuated when a 160 km cycle trial is preceded by RIPC in 
comparison to a time trial proceeded by a SHAM treatment. 
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Chapter 3: 
Study 1: Is there a rapid turnover of hs-cTnI and NT-proBNP during and after 2 
h of prolonged moderate intensity exercise in healthy active individuals? 
 
3.1. Introduction 
Most of the existing literature related to the release of cardiac biomarkers (cTnI/T 
and/or NT-proBNP) with acute bouts of prolonged exercise have employed limited pre-
post designs attached to field based competitions with older assays in elite athletes 
(Shave et al., 2010).  Though valued, much of the inconsistent data derived from these 
studies may be attributed to variations in the design employed, the participants studied 
and/or the assays used (Shave et al., 2010). It has been postulated that the competitive 
nature of these original research studies made it difficult to control many confounding 
variables such as the exercise dose and environmental stress (Apple et al., 2002; Laslett 
et al., 1996; Siegel et al., 2001; Lippi et al., 2008). 
 
In an important step forward, Middleton et al., (2008) performed a controlled 
laboratory-based study in 9 athletes who completed a self-paced treadmill marathon.  
In tandem with this design, cTnT was analysed from blood draws at 30 min intervals 
during exercise, as well as immediately and at 1, 3, 6, 12 and 24 h after exercise.   All 
of the athletes had a detectable rise in cTnT during exercise and 8/9 runners had 
detectable cTnT during recovery. This data would suggest all athletes performing 
substantial bouts of prolonged exercise might release cTn into their circulation and 
thus it could be considered as a normal/physiological or even obligatory release.  To 
date this design and experiment has not been replicated with newer assays (e.g. hs-TnI) 
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and in different participant groups and this provides part of the rationale for the initial 
study.   
 
The potential insight generated by a combination of a controlled exercise environment 
(exposure), the ability to assess lower levels of cTn using the new hs-cTnI assay and 
the recruitment of healthy but untrained participants is unique. Consequently, the aim 
of the first study in this thesis is to document the kinetics of hs-cTnI and NT-proBNP 
in response to 2 hr of endurance exercise in a controlled laboratory setting in young, 
untrained participants.  Blood samples will be collected during exercise and into early 
recovery. If hs-cTnI and NT-proBNP levels appear rapidly during prolonged exercise 
(i.e. within 2 hours) as well as drop below baseline within 3 hours post exercise, this 
could indicate a more rapid release and turnover than that which occurs with AMI.  
This would support reversible cardiomyocyte damage and/or sub-clinical 
haemodynamic stress as the overarching mechanism underpinning biomarker release 
with exercise.  
 
STUDY1: Hypothesis 1: Running for 2 hours on a motorised treadmill at moderate 
intensity will reveal a rapid turnover of cTnI, using the new high sensitivity assay, and 
NT-proBNP in moderately active adults. 
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3.2. Methods 
Participants 
In line with Middleton et al., (2008) study, nine healthy and active male participants 
(mean + SD; age 21 + 2 yr; stature 1.80 + 0.04 m; body mass 77.2 + 15 kg) volunteered 
to take part in the study.  Ethical approval was obtained from Liverpool John Moores 
University Ethics Committee prior to data collection. Participants were recruited from 
the Cheshire Regiment’s 1st team football squad (see Table 3.1).  All participants 
provided written informed consent.  The participants received a participant information 
sheet and were verbally informed of the procedures involved in the testing protocol, 
with any associated risks and their rights to withdraw from the study at any point 
clearly outlined.  All participants completed a health related questionnaire prior to 
undertaking any test (Appendix 1) to screen for medical conditions and/or a family 
history of cardiovascular disease. We specifically recruited participants with moderate 
levels of fitness who could complete the tasks required but who were not currently, or 
in the last 3 years, training for endurance competition  
 
Table 3.1. Participants’ characteristics  
Variables  Subjects’ characteristics  
Men 9 
Physical activity (h/wk) 15 + 0.4 
Running activity (km/week) 4 + 4 
Competitive running experience (km/week)   0 
Marathon or ultra-distance experience  
Treadmill running experience (km/week) 
0 
2 + 3 
  
Data are presented as mean + SD 
 
 40 
 
P
ag
e4
0
 
Protocol 
To improve familiarisation participants were asked to complete 2 visits to the 
laboratory at the Tom Reilly Building Liverpool John Moores University and be ready 
to start for 10am.  At visit 1 participants initially had their height and body mass 
measured and then performed a graded treadmill running test to volitional exhaustion.  
This test determined treadmill speed and target heart rate for the prolonged exercise 
trial in visit 2.   At visit 2, which was a minimum of 7 days after visit 1, the endurance 
trial was performed.  This lasted 120 min at 70 to 80% of peak heart rate that was 
determined from the initial maximal treadmill test.  Blood samples for the 
determination of hs-cTnT and NT-proBNP were performed at baseline (rest), at 30, 60, 
90 and 120 min of exercise and then 1 and 3 hours post-exercise (Figure 3.1). All 
participant were directed not to exercise intensely in the 48 hours before attending the 
laboratory.  Participants were asked to eat breakfast before attending the study and to 
avoid caffeine and alcohol for 24 hr before the assessments. Participants were allowed 
to drink water before and during exercise ad libitum, to maintain hydration.  The test 
occurred at least 3 hours after the participant’s last meal. 
 
Figure 3.1. Schematic of the blood collection protocol. 
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The height (m) and body mass (kg) of each participant was measured using a standard 
stadiometer (Seca, Germany) and electronic scales (Seca, Germany), respectively.  At 
the first visit after a general warm up of walking on the treadmill and stretching, the 
treadmill speed was set at an initial speed of 6 km.h-1 and the gradient set at 1%.  
During the test the running speed was increased in increments of 1 km.h -1 every minute 
until 13 km.h-1 was reached.  The treadmill speed was then kept constant and the 
gradient was increased 1% every minute until the test was voluntary terminated. 
Exercise HR was measured with an HR monitor (Polar S810i; Kempele, Finland) at 5 s 
intervals and maximum HR was recorded as the highest 30 s average value.    
 
In the prolonged treadmill test a general warm up of walking on the treadmill and 
stretching was performed before the treadmill speed was gradually increased to the 
target speed.  Timing of the 2 hr trial and HR were recorded from this point. During the 
run the subject was aware of the time, distance and speed.  The prolonged exercise trial 
was completed at 70 to 80% of maximum heart rate determined from the initial 
maximal treadmill test. Heart rate data was continuously recorded throughout the 
exercise trial and the participants were allowed to make small changes in treadmill 
speed for their own comfort at any stage. 
 
Blood Sampling and Analysis  
Blood samples were collected via an in-dwelling cannula. A small butterfly needle was 
inserted in to a vein with a cannula in the arm and left there for the duration of the 
exercise so that a total of 7 x 5 ml blood samples were collected using serum gel 
vacutainer (Becton Dickinson UK Ltd, Oxford UK).  After the sample had been 
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collected and removed the cannula was flushed with 10mL of 0.9% NaCl.  The 
insertion and maintenance of the venous cannula was performed by qualified staff.  
Patency of the cannula was checked regularly and saline flushes used if necessary.   
Collected whole blood samples was left to clot for approximately 60 min and then 
centrifuged at 1000 g at 18oC for 10 min. The serum was then drawn off with a 
disposable pipette (Effendorf, Hamburg, Germany), samples were divided into 3 
aliquot parts, and stored at -80oC for later analysis. Participants were encouraged to 
drink during exercise ad libitum to maintain euhydration.   
 
Cardiac troponin I was analysed using the hs-cTnI ADVIA Centaur CP TnI Ultra 
assay. The assay is a three-site sandwich immunoassay using direct chemilominometric 
technology.  A “Binary Lite” reagent was used to reduce non-specific binding. The 
antibodies in the ancillary reagent bind to troponin I in the sample based on guidelines 
from the Clinical & Laboratory Standards Institute. The market versions of the ADVIA 
Centaur assay have a lower detection limit that equates to the 99th percentile of a 
healthy population (20 ng/L).  The assay for our laboratory has an established 
diagnostic cut-off of 30 ng/L and values above this are considered to represent 
myocardial damage, with the current accepted cut-off for diagnosis of acute myocardial 
infarction (AMI) at 50 ng/L.     
 
The IMMULITE 2500 analyser was used for the quantitative measurement of the NT-
proBNP assay with an incubation of 10 minutes.  It is a two site chemiluminescent 
immunometric assay.  Based on guidelines (Siemens 2007) the IMMULITE 2500 
analyser employs a lower detection limit that equates to the 95th percentile of a healthy 
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population (50 ng/ml with a linear calibration range of 35,000 ng/ml). Values above 
125 ng/mL in patients younger than 75 years old reflects a clinically relevant outcome. 
 
Statistical Analyses 
Power analyses are problematic when some biomarkers are undetectable at rest or post-
exercise.  Consequently, we adopted an approach to recruit a motivated sample whose 
size was similar to previous studies.  The final sample consisted of 9 subjects, 
comparable to Middleton et al., (2008: n = 9) and Mousavi et al., (2009: n =8). All 
cohort data are reported as mean + SD unless otherwise stated.  hs-cTnI data were 
analysed individually and descriptively due to the likelihood of undetectable values at 
rest.  All NT-proBNP data (pre, during and post-exercise) were analysed using 
repeated measures one-way ANOVA and post-hoc pair-wise comparisons as 
appropriate.  All analyses were performed using Statistic Package for Social Science 
for windows version 17.0 (SPSS v17 for Windows, SPSS Inc IL, USA). 
 
3.3. Results 
All participants completed the 2 h motorised treadmill test at a mean speed of 8.0 + 0.8 
km/h and mean heart rate of 142 ±17 beats.min-1 (71 + 8% of measured maximum heart 
rate). 
 
Table 3.2 details individual hs-cTnI values at each blood draw for all participants.  All 
cTnI values were below the assay detection limit of 20 ng/L at baseline. During 
exercise no cTnI was detected in any sample. Post-exercise cTnI remained undetectable 
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in 7 of the 8 participants. The single participant with detectable hs-cTnI post exercise 
had a minor increase at post 60 min (22 ng/L) with a maximum value at 180 min post-
exercise (24 ng/L).  No value exceeded the clinical cut-off of 50 ng/L at any sample 
point. 
 
Table 3.2. Individual data for hs-cTnI (ng/L) 
SUBJECTS PRE EX 30 EX 60 EX 90 EX 120 R 60 R 180  
1 <20 <20 <20 <20 <20 <20 <20 
2 <20 <20 <20 <20 <20 <20 <20 
3 <20 <20 <20 <20 <20 <20 <20 
4 <20 <20 <20 <20 <20   22   24 
5 <20 <20 <20 <20 <20 <20 <20 
6 <20 <20 <20 <20 <20 <20 <20 
7 <20 <20 <20 <20 <20 <20 <20 
8 <20 <20 <20 <20 <20 <20 <20 
9 <20 <20 <20 <20 <20 <20 <20 
 
Pre=pre exercise sample, Ex=exercise samples, R=recovery samples, numbers are 
minutes through each component of the protocol 
 
There was a significant increase in NT-proBNP compared to baseline levels at all 
sample points (P<0.001).Values at EX120, R60 and R120 were higher than EX30 with 
heterogeneity of response noted as mean values increased (P > 0.05).   Mean and SD 
for NT-proBNP peaked at R60 post-exercise.  Mean NT-proBNP values at 180 min 
post-exercise was still close to the 125 ng/l clinical cut-off and raised above baseline 
levels (Table 3.3). The subject (4) with detectable cTn post-exercise had an 
exaggerated NT-proBNP response with a peak (365 ng/L) 60 min post-exercise 
although there was then a rapid drop at 180 min post-exercise (65 ng/L).  The 
participants who were presented with cTn levels below URL had a highly variable NT-
proBNP response, with no clear pattern of high or low responders. 
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Table 3.3. Individual and mean cohort data for NT-proBNP (ng/L) 
SUBJECTS PRE EX 30 EX 60 EX 90 EX 120 R 60 R 180  
1 80 90 120 138 194 210 170 
2 64 46 43 58 89 120 158 
3 40 75 90 120 147 107 87 
4 36 50 88 121 223 365 65 
5 38 50 75 83 102 127 161 
6 43 55 76 104 137 155 210 
7 50 63 90 62 55 132 86 
8 41 59 73 86 58 96 77 
9 52 76 83 89 120 203 66 
MEAN 49 63 82 96 125 168 120 
SD 14 15 20 27 57 84 54 
 
Pre=pre exercise sample, Ex=exercise samples, R=recovery samples, numbers are 
minutes through each component of the protocol 
*Significant increase in NT-proBNP compared to baseline levels at all sample points 
(P<0.001). 
  
 
3.4. Discussion 
To the authors knowledge this is the first study to utilise the new hs-cTnI assay as well 
as the NT-proBNP assay in a controlled laboratory trial with healthy recreationally 
active participants, to determine the cardiac biomarker response to 2 h of prolonged 
running on a motorised treadmill. The key findings were that; 1) detectable cTnI was 
observed in only 1/9 participants in the early recovery period, and 2) a progressive rise 
in NT-proBNP across exercise and early recovery was noted in all subjects, with partial 
recovery 3 hr post-exercise. 
 
The current study’s observation of only sporadic (1/9) and very low (sub-clinical cut-
off of 30 ng/l) values for hs-cTnI in response to 2 h of treadmill running are somewhat 
at odds with the prevailing literature (Middleton et al., 2008).  Despite this, similar 
small percentages of “cTnI-responders” have been reported in field-based studies of 
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competitive endurance running (Abasher et al., 2010) and study-to-study variability is 
well noted in narrative reviews (Shave et al., 2010) and meta-analyses (Shave et al., 
2007).  In adopting a research design with multiple blood draws to more fully describe 
the cardiac biomarker kinetics during and post-exercise we were surprised that we did 
not see similar cTn data to that published by Middleton et al., (2008).  Middleton et al., 
(2008) described a cTnT increase in all of the athletes completing a treadmill-based 
marathon in athletes. The consistency of response, subject-to-subject was notable 
leading the authors to suggest that cTnT release with prolonged exercise may be an 
obligatory and physiological response.  We can only speculate as to the discrepancy 
between the current study and Middleton’s data but some details are worthy of note.  
Middleton et al., (2008) studied highly trained athletes completing a treadmill-
marathon as quickly as possible (these participants would have been more highly 
trained and exercising at a higher absolute and relative intensity for c. 3.5 hrs).  These 
differences (training status and exercise exposure) may provoke different cTn 
responses to prolonged exercise (Shave et al., 2010) but have rarely been 
systematically studied in controlled environment.  There is some suggestion that higher 
exercise intensities and trained participants are more likely to demonstrate a cTn 
response to prolonged exercise but we note that Eijsvogels et al., (2010) reported 
positive cTn responses in low fit participants undertaking prolonged walking-exercise, 
albeit using an older assay.  Notably Middleton et al., (2008) also used a 3rd generation 
cTnT assay, as opposed to hs-cTnI, and different detection limits may be relevant 
(Eijsvogels et al., 2010). 
 
There is also some in-consistency when reporting cTnI versus cTnT in response to 
exercise with the two molecules having different molecular weights possibly impacting 
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their “exercise-response” (Klinkenberg et al., 2016). Further cTnT was at a maximum 2 
h post-exercise vs. 5 h post-exercise for cTnI. 
 
The implications that we draw is that exercise-induced cTnI release is likely dependent 
on a range of potentially interacting factors (assay, fitness status, exercise volume) and 
as such is extremely difficult to predict.  The sporadic release and the sub-clinical 
threshold response when cTnI was detectable do not appear to support irreversible cell 
death as the cause of any change in cTnI in this specific sample undertaking the 
specific exercise stimulus. 
 
The appearance and rise of NT-proBNP in response to the current exercise exposure 
was variable.  NT-proBNP data rose in all participants during exercise with some 
evidence of recovery early post-exercise in most subjects. Evidence from other 
researchers suggest that NT-proBNP values for healthy untrained and athletes are not 
elevated under resting conditions but can be substantially increased after prolonged 
endurance events (Scott et al., 2009).  High intensity exercise, in healthy individuals, 
over shorter events, such as 30 to 60 min, has also resulted in an increase in NT-
proBNP (Vidotte et al., 2005; Lippi et al., 2008).  Consequently, the rise in NT-
proBNP is the current study supports previous research. 
 
To date, most of the available literature related to NT-proBNP release with exercise 
comes from pre - and post-endurance event data in well-trained athletes (e.g. Scott et 
al., 2009).  To the best of our knowledge this study represents one of the first attempts 
 48 
 
P
ag
e4
8
 
to detail NT-proBNP kinetics in response to controlled but prolonged exercise 
exposure in healthy and recreationally active young participants. A progressive rise 
with exercise duration points to the importance of this facet of exercise and supports 
some previous data (Nie et al., 2011; Carranza et al., 2011) in different participant 
groups (children) and various sports.  The fact that most data were elevated above 
clinical cut-off limits is consistent with previous data (Scott et al., 2009) but must be 
interpreted, clinically, with some caution.  Whilst mean cohort data peaked at 60 min 
post exercise (169 ng/L) this over simplifies a heterogeneous individual response and 
clearly by 180 min post exercise the NT-proBNP mean data was dropping back 
towards baseline.   
 
This suggests two things; 1) individual variability is likely a complex and composite 
response to multiple between subject differences (age, fitness, health) that have not 
been adequately studied previously, and 2) rapid recovery of NT-proBNP from an 
exercise stress suggests a transitory and likely physiological response likely mediated 
by the increased cardiac stretch that occurs with exercise exposure as a means to 
increase preload and thus stroke volume during endurance exercise. 
 
If NT-proBNP release is obligatory with endurance exercise exposure one might 
hypothesise that repetitive bouts of exercise should provoke the same NT-proBNP 
response.  This has not been studied to date and will be the focus of the next Chapter.  
Likewise, the response of cTn to the same bout of exercise, in the same subjects 
(repeatability) has rarely been studied before in a controlled environment.  This would 
likely inform the debate about the clinical importance of cTn changes with exercise and 
 49 
 
P
ag
e4
9
 
whether it reflects reversible or irreversible cell death and provides a secondary 
rationale for the next study.  
 
Limitations  
The limited fitness of the participants and lack of familiarisation employed in the 
current study led to lower exercise intensities and volumes being completed in the 2 hr 
trial.  This may have led to reduced cTnT data. The phlebotomist had difficulties taking 
blood from some participants and it may be a good idea to reiterate the importance to 
the participants that they come to the laboratory euhydrated.  The use of multiple blood 
draws and 2 hours on the treadmill will be continued in the next Chapter.  
 
3.5. Conclusion  
In conclusion, moderate intensity prolonged running in healthy males resulted in a 
limited release of cTn (as detected by a new hs assay) as well as a significant, and 
exercise-duration dependent elevation in NT-proBNP.  The rapid elevation and 
removal during early recovery suggest these changes have limited clinical relevance 
and possibly reflect normal physiological processes. 
 
Study 2 will develop this work by employing and repeated, identical exercise bouts in 
the same participants 1 and 12 weeks after this first exercise exposure. This will 
provide an attempt to address the issue of repeatability of exercise induced cardiac 
biomarker elevation.  
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Chapter 4:  
Study 2: The short and long-term repeatability of the hs-cTnI and NT-proBNP 
response to a 2 h bout of prolonged moderate intensity running in healthy active 
individuals. 
 
4.1. Introduction 
There is ample evidence that single bouts of exercise (across the intensity and duration 
domains, in a range of participant groups and in different settings) will lead to the 
appearance of biomarkers of cardiac insult/damage and stress (Shave et al., 2007; 
2010).   We have added to this database in the previous chapter, utilising a new hs-cTnI 
assay as well as providing greater insight into the exercise and recovery kinetics of 
NT-proBNP.  Further we utilised multiple blood sample times to document the kinetics 
of the biomarker responses in healthy non-athletic adults that has rarely been described 
previously (Eijsvogels et al., 2010).  We described limited hs-cTnI release and a more 
consistent increase and recovery in NT-proBNP.  Given the nature of the kinetic data 
we proposed that these biomarker changes represented low or negligible levels of 
clinical risk and probably reflected normal physiological adaptation to endurance 
exercise.   
 
We, and others, have conceived the idea that if these responses were highly repeatable 
this would provide further evidence of the obligatory or physiological nature of these 
biomarker responses.  Somewhat surprisingly, the repeatability of cardiac biomarker 
responses to repeated exercise bouts, in a controlled environment is scarce (Nie et al., 
2011). Nie et al., (2011) looked at the effect of repeat endurance runs (same speed and 
HR) on the same day, approximately 4 hours apart.  This does not reflect the ideal 
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design to assess repeatability due to the limited recovery period between exercise bouts 
and the potential for a time of day effect (Chan-Dewar et al., 2013).  Despite this, the 
data from Nie et al., (2011) indicated that the cTnT response to the second bout of 
exercise was qualitatively similar yet quantitatively “blunted” .  Whilst speculative, it 
may suggest that reversible cardiomyocyte damage from bout one is attenuated in a 
subsequent bout.  Whether this is the case with exercise performed 1 and 12 weeks 
after an initial exercise trial is not known. The plan to utilize 2 repeat bouts at different 
times allows us to explore the potential for a “repeat-bout” effect when performing the 
same exercise stimulus.  
 
Repeatability of cardiac biomarker responses to exercise has received very little 
attention (Tian et al., 2012). If the exposure was repeatable this study may help with 
our understanding of the impact or mechanisms involved in cTn elevation during 
exercise.   Consequently, the specific aims of this second study were; (1) to analyse the 
cardiac biomarker response to two identical bouts of exercise performed exactly 7 days 
apart in a controlled environment (termed Week 0 and Week 1), and (2) compare the 
cardiac biomarker response to a further exercise bout 12 weeks after the initial exercise 
exposure. 
 
STUDY 2: Hypothesis 2a: Cardiac biomarker responses to the same exercise bout 
employed in STUDY 1, are highly repeatable after a period of 7 days between exercise 
tests in the same participants.  
 
STUDY 2: Hypothesis 2b: Cardiac biomarker responses to the same exercise bout 
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employed in STUDY 1, and Hypothesis 2a, will be highly repeatable after a period of 
12 weeks between the first and last exercise test in the same participants. 
 
4.2. Methods 
Participants  
Eight healthy and active male participants (mean + SD; age 22 + 2 years old; stature 
1.80 + 0.04 m; body mass 82.6 + 11.3 kg) volunteered to take part in the study.  All 
participants were asked to complete three similar (speed, HR) prolonged runs on a 
motorised treadmill under the same conditions in week 0, seven days later in week 1 
and then after a further 12 weeks. These participants are the same as those reported in 
Chapter 3 and were asked to maintain a consistent approach to diet and physical 
activity over the duration of the study. Ethics approval was granted by Liverpool John 
Moores Ethics Committee and all participants provided written informed consent 
before participation. 
 
Eight participants exercised at a constant (over the 3 bouts) relative intensity for 120 
min on a motorised treadmill that equated to 70 to 80% of peak heart rate, which was 
determined from the initial maximal treadmill test from Study 1.  Specific controls 
were placed upon the repeated runs including the same; time of day, diet and hydration, 
prior exercise and environmental conditions. Venous blood was drawn, to determine 
hs-cTnI and NT-proBNP, at baseline (rest), at 30 min, 60 min, 90 min and 120 min of 
exercise and then 1 hour and 3 hours post-exercise for both trials. Heart rate data was 
recorded continuously throughout all treadmill runs. 
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Protocol  
All assessment and data analysis protocols were consistent between Week 0, Week 1 
and Week 12 and thus are reported in the previous Chapter.  
 
Statistical Analyses 
All data are reported as mean ± SD unless otherwise stated. hs-cTnI was analysed 
individually and descriptively due to the likelihood of undetectable values at baseline.  
Repeatability was assessed qualitatively by assessing those participants who had 
detectable values in all three trials. 
 
All NT-proBNP data (pre, during and post-exercise) were analysed using repeated 
measures (for time and trial) two-way ANOVA and post-hoc pair-wise comparisons as 
appropriate.  This approach determined the systematic changes in NT-proBNP kinetics.  
For the purposes of assessment of random variance in this biomarker, peak NT-proBNP 
values for all subjects in each of the trials were compared using Pearson product-
moment correlation coefficients.  All analyses were performed using Statistic Package 
for Social Science for windows version 17.0 (SPSS v17 for Windows, SPSS Inc IL, 
USA). 
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4.3. Results 
The 8 participants completed exercise tests in week 0 and week 1. Two participants did 
not complete the 12 week study due to sports related injury.  The 8 participants who 
completed the Week 0 treadmill run did so at a mean speed of 7.6 + 0.7 km/h and heart 
rate of 148 + 17 beats.min-1 (72 + 9% of measured maximum heart rate).  The same 
participants completed the treadmill run in Week 1 at a mean speed of 7.4 + 0.5 km/h 
and a mean heart rate of 137 + 20 beats.min-1 (64 + 8% of actual heart rate maximum).  
The 6 participants who completed the run in Week 12 had a mean speed of 7.5 + 0.4 
km/h and a mean heart rate of 141 + 3.2 beats.min-1 (65 + 8% of maximum heart rate). 
For the 6 runners who completed all tests there was no significant difference in speed 
and HR across the 0 and 12 week trials (> 0.05). 
  
Table 4.1 demonstrates the cTnI responses to three treadmill exercise bouts for the 
participants who completed the tests.  In Week 0, Week 1 and Week 12 cTnI values 
were below the clinical assay detection limit of 50 ng/L, in all participants, at baseline 
and during exercise. 
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Table: 4.1. Individual data for hs-cTnI in Week 0, Week 1 and week 12 (ng/L) 
SUBJECT
S 
WEEK PRE EX 30 EX 60 EX 90 EX120 R 60 R 180 
1 
 
0 
1 
12 
<20 
<20 
<20 
<20 
<20 
<20 
<20 
- 
<20 
<20 
<20 
<20 
<20 
<20 
<20 
<20 
<20 
<20 
 <20 
<20 
<20 
 
2 
 
0 
1 
12 
<20 
<20 
<20 
<20 
<20 
<20 
<20 
<20 
<20 
<20 
<20 
<20 
<20 
<20 
<20 
<20 
<20 
<20 
<20 
<20 
<20 
 
3 
 
0 
1 
12* 
<20 
<20 
- 
 
<20 
<20 
- 
 
<20 
<20 
- 
 
<20 
<20 
- 
 
<20 
<20 
- 
 
<20 
<20 
- 
 
<20 
<20 
- 
 
4 
 
0 
1 
12 
<20 
<20 
<20 
<20 
<20 
<20 
<20 
<20 
<20 
<20 
<20 
<20 
<20 
<20 
<20 
22 
30 
<20 
24 
 33 
<20 
 
5 
 
0 
1 
12 
<20 
<20 
<20 
<20 
<20 
<20 
<20 
- 
<20 
<20 
<20 
<20 
<20 
<20 
<20 
<20 
<20 
<20 
<20 
<20 
<20 
 
6 
 
0 
1 
12 
<20 
<20 
<20 
<20 
<20 
<20 
<20 
<20 
<20 
<20 
<20 
<20 
<20 
<20 
<20 
<20 
<20 
25 
<20 
<20 
38 
 
7 
 
0 
1 
12* 
<20 
<20 
- 
<20 
<20 
- 
<20 
<20 
- 
<20 
<20 
- 
<20 
<20 
- 
<20 
<20 
- 
<20 
<20 
- 
 
8 
 
0 
1 
12 
<20 
<20 
<20 
<20 
<20 
<20 
<20 
<20 
<20 
<20 
<20 
<20 
<20 
<20 
<20 
<20 
<20 
<20 
<20 
<20 
<20 
 
Pre=pre exercise sample, Ex=exercise samples, R=recovery samples, numbers are 
minutes through each component of the protocol 
* subjects that did not complete the 12 week run  
 
There was only one participant (4) with detectable cTnI in both the week 0 and week 1 
trials and the variability in actual concentrations was very small  (during week 0 at 180 
min there was a value of 24 ng/l and at week 1 there were detectable cTnI at 60 and 
180 min of recovery, 30 and 33 ng/l). All other participants had non-detectable values 
in both weeks before, during and after exercise, reflecting consistent outcomes at a 
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global level (responder vs. non-responder).  In week 12 the “responder” in week 0 and 
1 (4) had no detectable cTnI throughout the trial. One different participant (6) had 
detectable hs-cTnI of 25 and 38 ng/l (the highest value reported in the study) at 60 and 
180 min of recovery in Week 12 but had not had any detectable values in week 0 and 1.  
 
Figure 4.1 and Table 4.2 demonstrate the cohort and individual NT-proBNP response 
to the three identical exercise bouts.  There was a main effect of exercise duration 
(P<0.001) as NT-proBNP rose with exercise duration in all weeks.  Slightly higher 
values at rest were noted during week 12 but there was no main effect of week 
(P=0.429).  Despite this there was a significant interaction effect (P<0.004) with data 
in Week 1, generally higher and peaking earlier (Ex 120) compared to a later peak for 
both Week 0 (R 60) and Week 12 (R180).  The maximum concentration of NT-proBNP 
was 388 ng/L with 21 values out of 64 that exceed the clinical cut off value (125 ng/l). 
This was quite marked within and between individuals in the NT-proBNP response to 
the 3 exercise trials. Peak NT-proBNP levels were compared within individuals across 
trials.  Correlation coefficients between trials 0 and 1, 0 and 12 and 1 and 12 were 
small to moderate in nature (r = 0.036, r = 0.23 and r = 0.39 respectively; all P>0.05).  
 
  
 57 
 
P
ag
e5
7
 
Figure 4.1. Mean cohort data for NT-proBNP responses in Week 0, Week 1 and 
Week 12 
 
 
Pre=pre exercise sample, Ex=exercise samples, R=recovery samples, numbers are 
minutes through each component of the protocol 
 
 
Table 4.2. Individual NT-proBNP data in Week 0, Week 1 and Week 12 (ng/L) 
Subjects Week Pre Ex 30 Ex 60 Ex 90 Ex 120 R 60 R 180  
1 
0 80 90 120 138 194 210 170 
1 75 88 94 100 150 175 183 
12 124 203 107 88 90 56 70 
2 
0 64 46 43 58 89 120 158 
1 90 122 136 185 210 147 66 
12 83 55 90 110 134 151 88 
3* 
0 40 75 90 120 147 107 87 
1 115 129 81 107 87 120 80 
12 - - - - - - - 
4 
0 36 50 88 121 223 365 65 
1 83 69 115 249 330 388 406 
12 105 122 135 183 226 283 306 
5 
0 43 55 76 104 137 155 210 
1 56 67 83 106 141 93 107 
12 31 44 48 60 86 96 108 
6 
0 50 63 90 62 55 132 86 
1 40 72 133 245 194 163 34 
12 62 40 95 116 137 231 494 
7* 
0 41 59 73 86 58 96 77 
1 56 63 87 105 131 108 93 
12 - - - - - - - 
8 
0 52 76 83 89 120 203 66 
1 78 84 96 124 241 127 99 
12 58 98 124 106 131 158 142 
0
50
100
150
200
250
300
350
400
Pre test 30 mins 60 mins 90 mins 120 mins Rest 60 minsRest 180 mins
N
T-
p
ro
B
N
P
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n
g/
L)
WEEK 0 WEEK 1 WEEK 12
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Pre=pre exercise sample, Ex=exercise samples, R=recovery samples, numbers are minutes through each 
component of the protocol. 
 
4.4. Discussion 
The aim of this study was to analyse the repeatability of hs-cTnI and NT-proBNP 
responses to three similar prolonged runs on a motorised treadmill, with 1 and 12 
weeks between bouts.  The key finding were: 1) detectable hs-cTnI was identified in 
the same single runner in Week 0 and Week 1 trials and for the remaining 7 
participants no detectable hs-cTnI was observed in either runs – suggestive of gross 
levels of repeatability [responders vs. non-responders], 2) at week 12 the responder in 
Week 0 and Week 1 did not demonstrate an elevated cTn although one different 
participant did who had not had a detectable level in week 0 and 1 providing limited 
support for a repeat bout effect, and 3) individual NT-proBNP responses were quite 
variable although an exercise duration related elevation in NT-proBNP was noted in all 
weeks although the magnitude of the response was somewhat augmented after the 
Week 1 run and the recovery kinetics were delayed in Week 12.  Individual variation in 
peak NT-proBNP data suggest this phenomenon is not highly repeatable.  
 
The current study’s observation of low number of detectable cTnI values in response to 
2 h of repeat prolonged runs (1/8) for Week 0; Week 1 (1/8) and Week 12 (1/7)  is 
somewhat in line with the prevailing literature where moderate intensities and 
prolonged exercise is accomplished (Abasher et al., 2010; Shave et al., 2010).  In one 
of the few repeated exercise trials, Nie et al., (2011) reported similar low levels of 
cTnT after treadmill running in trained adolescents. There is, however, as noted in the 
previous chapter some disparity between the small number of detectable cTnI samples 
in comparison to a previous controlled laboratory study (Middleton et al., 2008) with 
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multiple assay points during and post-exercise.  Middleton et al., (2008) demonstrated 
an elevation in cTnT in all subjects at some point during exercise or recovery.  The 
lower response rate of only 1 participant per trial in the current study likely reflects a 
combination of assay type, exercise intensity and duration as well as training status of 
the participants. 
 
The current data reflects a largely repeatable phenomenon in a gross (responder vs. 
non-responder) sense.  The subject that had levels above clinical cut off during Week 0 
also had elevated levels during Week 1 and participants that did not respond to 
elevated cTn during Week 0 did not during Week 1. The participant that responded 
during Week 0 and Week 1 but not Week 12 may indicate that there was a repeat bout 
effect after 7 days between the Week 0 and Week 1 but not after 12 weeks. 
Alternatively, the lack of response in week 12 may reflect a change in training status . It 
was difficult to manage what the participants did during the 12 weeks between trails.   
The subject that had higher readings during Week 0 and Week 1 may have changed the 
intensity and duration of training during the 12 weeks. This lack of evidence of a 
“repeat bout” effect during 60 min of treadmill running indicates that cardiac tissue 
responses to exercise do not match those of damaging skeletal muscle responses. This 
may be attributable to the fact that damaging exercise for skeletal muscle often 
contains a high eccentric component which is hard, if not impossible, to replicate in 
cardiac tissue. 
 
There was some evidence of cohort consistency with the analyses of NT-proBNP as all 
participants had elevated NT-proBNP during the three trials. There were, however, 
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quite marked week-to-week differences in data in the same individual. Week 1 did 
show a slightly augmented profile and then reduces to similar concentrations achieved 
during Week 0 which may indicate evidence of a repeat bout effect after an identical 
exercise bout 7 days before and 12 weeks to reduce the repeat bout effect. The altered 
R 180 in week 12 may be as a result of a reduced sample size affecting statistical 
evidence. Correlation coefficients for peak NT-proBNP data were low to moderate, 
likely indicative of substantial variability in the individual response to repeated bouts 
of exercise.  
 
To the best of our knowledge this is the first study to look at the repeatability of 
cardiac biomarker response to prolonged exercise (with repeated blood draws) with 1 
and 12 weeks separating repeated bouts in a controlled environment.  Data for the hs-
cTnI assay provide some support for a cardiac biomarker release being a repeatable 
phenomenon.  It would be somewhat presumptuous to say that the replication of one 
positive hs-cTnI assay definitively supports this as a repeatable phenomenon at an 
individual level, but this does reflect the balance of responders and non-responders. 
The lack of individual repeatability in NT-proBNP data means that one-off tests in 
participants must be treated with some caution as exercise may provoke quite profound 
effects. 
 
There were a number of NT-proBNP values above the clinical cut-off (125 ng/l).  
Clearly in the absence of other clinical indicators (including a general lack of hs-cTnI) 
and rapid removal in many cases during recovery this again likely represents a 
physiological process.  That said, in situation of clinical presentation after exercise 
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(maybe in a race medical tent) presentation with a high NT-proBNP (if assayed) should 
be interpreted in the full knowledge of likely recent exercise exposure. 
 
Limitations  
The use of eight participants for week 0 and 1 and 6 participants for week 12 may have 
restricted statistical significance.  The detection limit for the hs-cTn assay should be 
lowered in further work in an attempt to uncover resting cTn levels and lower levels of 
exercise response. 
 
4.5. Conclusion  
In conclusion, three similar bouts of prolonged treadmill running in healthy untrained 
males in weeks 0, 1 and 12 resulted in a limited (gross level) repeatable cTnI response, 
with no real evidence of a repeat bout effect.  NT-proBNP rose with exercise and into 
recovery in all weeks but peak values were slightly higher in Week 1 and 12 with a 
delayed recovery in Week 12. Interestingly individual NT-proBNP could vary quite 
markedly in specific individuals and correlational analysis suggests that this is quite a 
variable phenomenon. 
 
In study 3 the potential mediating role of ischaemia will be evaluated by the 
application of remote ischemic preconditioning (RIPC) before one trial compared to a 
SHAM intervention. Participants will undertake two 1 hour cycle time trials in a 
controlled laboratory environment with biomarkers and cardiac function assessed 
during early recovery. Of note the detection level for cTn will be lowered. 
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Chapter 5:  
Study 3: The impact of remote ischemic preconditioning on cardiac biomarkers 
and functional response to endurance exercise. 
 
This chapter has already been published and copyright assigned 
Cocking, S., Landman, T., Benson, M., Lord, R., Jones, H., Gaze, D., Thijssen, D.H.J. 
and George, K (2017). The Impact of Remote Ischaemic Preconditioning on Cardiac 
Biomarker and Functional Response to Endurance Exercise, Scandinavian Journal of 
Sports Medicine, 10, 1061-1069. 
doi: 10.1111/sms.12724.  
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Chapter 6:  
Study 4: The impact of remote ischemic preconditioning (RIPC) on the cardiac 
biomarker and cardiac functional response to a 160 km cycle ride. 
 
6.1. Introduction  
In the previous chapter, we employed a repeated measures research design to assess the 
impact of RIPC (compared to a SHAM protocol) on the cardiac biomarker and 
functional responses during the early recovery period after a 60 min cycle time-trial. 
The key outcome was a significant main effect of trial on cTnT values. cTnT values 
were lower in the RIPC trial than the SHAM trial across the recovery period although 
there was no significant time-by-trial interaction. Due to the lower levels of cTnT 
during recovery in the RIPC trial it was concluded that this provided the first, albeit 
limited, support for a role of ischaemia in the appearance of cTnT post-exercise.  
Clearly further exploratory work was required. 
 
Initially, it would be sensible, in any follow-up study, to address the potential 
limitation(s) of the previous Chapter, specifically related to the limited volume of the 
exercise challenge.  Whilst there is evidence that shorter bouts of exercise may result in 
cTnT appearance during recovery (Shave et al., 2010) there is a much larger evidence-
base with the potential for a more marked individual and cohort cTnT response with a 
greater exercise challenge (Douglas et al., 1987; Scott et al., 2009; George et al., 2010; 
Shave et al., 2010).  In constraining the exercise in the previous chapter to a 
laboratory-base, for valid reasons of control of the environmental challenge (for 
example), the exercise task was limited to what could be comfortably completed and 
acceptable to the participants.  The adoption of a 60 min TT as the exercise exposure is 
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at the lower end of exercise duration and volumes employed in previous exercise-
related biomarker studies (Dawson et al., 2003; Scharhag et al., 2007; Shave et al., 
2010).  The use of the hs-cTnI assay in the current study, rather than cTnT used in the 
last study, allows for more direct comparisons with Chapters 3 and 4 and the continued 
use of a lower detection limit (now available in the hs-cTnI assay) will help in our 
understanding of cTn elevation at the lower level of detection.  By adopting a field-
based exercise protocol in the current chapter the exposure to exercise is closer to 
replicating descriptive studies of cTn and NT-proBNP appearance in prolonged 
endurance-based athletes (Neilan et al., 2006; Scott et al., 2009).  A greater exercise 
exposure (duration and volume) places the heart under much greater and sustained 
hemodynamic and metabolic load and potentially provides an ideal research design to 
further evaluate the impact of RIPC, and by association the role of ischaemia, on cTn 
appearance with exercise. 
 
We have retained the repeated measures research design with a SHAM comparison to 
maintain internal validity whilst the change in exercise exposure and setting increases 
external (ecological) validity.  We also retained the technical approach to RIPC that 
was pioneered in the seminal study of Murry et al., (1986) and has been developed by 
recent research in this field (Whittaker & Przyklenk et al., 1994; Whittaker & 
Przyklenk, 2011). Specifically the application of a RIPC on both legs and both arms in 
a repetitive fashion over 40 min, prior to the exercise exposure, is targeted at 
maximising the RIPC stimulus. Consequently, this chapter will monitor the release of 
cardiac biomarkers of damage (hs-cTnT) and dysfunction (NT-proBNP) as well as non-
invasive measures of cardiac function after repetitive 160 km endurance cycling bouts, 
for regionally competitive club cyclists, in a real-world environment. If the elevation of 
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biomarkers and the reduction in cardiac function are (partially) related to ischaemia we 
would hypothesise a higher and more divergent response in hs-cTnI, NT-proBNP and 
indices of cardiac function after a 160 km cycle ride (c. 6 hr) preceded by SHAM as 
opposed to RIPC.   
 
STUDY 4: Hypothesis 4: Exercise-related changes in cTn, NT-proBNP and cardiac 
function will be attenuated when a 160 km cycle trial is preceded by RIPC in 
comparison to a time trial proceeded by a SHAM treatment. 
 
6.2. Methods  
Participants  
Nine male competitive cyclists (Mean + SD; Age 40.2 + 6.2 yr; Body mass 76.0 + 9.5 
kg; Height 175.8 + 6.9 cm; BMI 22.0 + 1.4) were recruited via personal contact with a 
local cycling club. Recruitment was on the basis that all participants could complete a 
160 km cycle trial at an average pace of 32 to 33 km/h, in order to facilitate a team 
cycling exposure that would reflect a club “race-day”, as well as being available and 
able to complete two rides over an identical course 7 days apart.  All participants were 
screened using a medical health questionnaire to determine the presence of personal or 
an early family history of cardiovascular disease.  All participants were free from 
current illness or injury and self-reported no significant interruptions or alterations in 
training within the last 4 weeks.  The study received Liverpool John Moores Ethics 
Committee approval and all subjects provided written informed consent after due 
consideration of the participant information sheet. 
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Table 6.1. Study 3 participants’ characteristics (n = 9) 
Variables  Subjects’ characteristics  
Men 9 
Physical activity (h/wk) 15 + 1 
Cycling activity (km/week) 120 + 4 
Competitive cycling experience (yrs)   8 + 3 
Participants with ultra-distance experience (cycling > 6hrs) 9 
  
Data are mean + SD 
 
Protocol 
In a randomised, controlled single-blind crossover design participants completed two 
field based 160 km cycle ride.  Participants received either a RIPC or SHAM protocol 
immediately before completing each cycle ride.  Both cycle rides started at 9:30 am to 
reduce the effects of circadian variation (Atkinson and Reilly, 1996). The two trials 
were separated by a minimum of 7 days recovery.  Although we could not control 
environmental exposure for both rides the cyclists were asked to ride at the same 
intensity irrespective of ambient conditions. All participants were able to self-monitor 
heart rate and performance data (speed, distance etc.) in a continuous manner during 
both rides. For both rides the participants were asked to refrain from exercise as well as  
caffeine and alcohol intake for the 24 hr prior to each trial.  Participants were asked to 
arrive at the laboratory on both test days at 7 am fully hydrated and having consumed 
their personal standardised breakfast that was repeated for both trials.  To help with 
familiarity and practicality the participants contributed to the design of the 160 km 
route. Immediately after RIPC or SHAM riders began the 160 km cycle rides. The 
riders rode together to achieve the highest average pace for each trial whilst being 
encouraged to make small adjustments to their route to attempt to match similar 
exercise exposure (duration and intensity) on both rides. The average elevation gain for 
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the two rides was planned at 735 metres.  Heart rate, speed, calories and elevation were 
continually assessed using their own individual bike tools (Polar, T31; Garmin 500 or 
550 models) and uploaded to an online programme for further analysis 
(www.Strava.com). Participants were instructed to take in fluids and food ad-libitum.   
 
Before (PRE), immediately (POST-0H) and 1 hr into recovery (POST-1H) after both 
cycle trials venous blood samples (to determine cardiac biomarker levels) and an 
ultrasound echocardiogram (to assess cardiac function) were completed. 
 
Remote ischemic preconditioning (RIPC) and SHAM procedure  
Remote ischemic preconditioning was performed in the supine position using the 
bilateral occlusion technique to achieve acute limb ischaemia in line with the methods 
employed in the last chapter and during a running exercise study by Bailey at al., 
(2012).  In the present study participants were randomised into either RIPC or SHAM 
groups for the first cycle trial and then they had the reverse procedure in the second 
trial.  Automated pressure cuffs (Hokanson, Washington, USA) and manual pressure 
cuffs (Accuson, UK) and was consistent with the approach adopted in the previous 
chapter.  Two blood pressure cuffs were rapidly inflated to 220 mmHg on the 
ipsilateral upper right bicep and lower left thigh to block arterial inflow for 5 minutes 
and then rapidly deflated.  Cuffs were then changed to the opposite limbs (left bicep 
and lower right thigh) before inflating to 220 mmHg again.  This protocol was repeated 
4 times (total time of ischaemia reperfusion was 40 minutes). For the SHAM protocol 
the participants followed the same protocol as above but cuffs were only inflated to 20 
mmHg which did not disrupt arterial blood flow. 
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Blood Sampling Procedure 
A trained phlebotomist withdrew 5 ml blood samples using repetitive venepuncture to 
assess cTnI and NT-proBNP.  At each blood draw 5 mL was taken from the antecubital 
vein with the subject in the sitting position, samples were collected using serum gel 
vacutainer (Becton Dickinson UK Ltd, Oxford UK).  After the whole blood had been 
collected it was left to clot for approximately 60 min and centrifuged at 1000 g at 18oC 
for 10 min. The serum was then drawn off with a disposable pipette (Effendorf, 
Hamburg, Germany), samples were divided into 3 aliquot parts, and stored at -80oC for 
later analysis. 
 
Cardiac Troponin  
In the previous Chapter a hs-cTnT assay was employed whereas in this study we used a 
hs-cTnI assay. The use of this assay allowed the lower end to be “opened up” with the 
view of identifying lower levels of cTnI. Whilst many studies have employed 
assessments of both cTnI and cTnT there have been small differences in data from the 
assays (Rifai et al., 1999; Urhausen et al., 2004). Most of these differences should be 
negated by a hs-assay.  Given the absolute cardiac specificity of cTnI and the use of the 
hs-cTnI assay in Chapters 3 and 4 we felt it made sense to move to this assay when the 
new lower detection limit became available. Serum samples were analysed in a single 
session for the presence of cTnI using the hs - TnI-Ultra assay for the ADVIA Centaur 
(Siemens Healthcare Diagnostics, Frimley, UK). The detection limit of the instrument 
was 0.006 μg/L, upper limit 50 μg/L. The manufacturers claim was 10% CV at 0.03 
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μg/L with a 99th centile of 0.04 μg/L.  The current accepted cut-off for diagnosis of 
AMI is 50 ng/L. 
 
N-terminal pro-B-type natriuretic peptide (NT proBNP): NT proBNP levels was 
assessed with the chemiluminescent sandwich immunoassay using the Immulite 2500 
(Siemens Healthcare Diagnostic Frimley, UK). The minimum detection limited for this 
assay is 20 ng/L with a maximum of 35000 ng/L.  The inter-assay % coefficient of 
variation was 5.0 to 4.0% with a range of 40.9 to 32096 ng/L.    
 
Cardiac Function  
A trained cardiac sonographer followed the guidelines set by American Society of 
Echocardiography (Lang et al., 2015). A 2 dimensional, transthoracic echocardiogram 
was performed with the participant resting in the left lateral decubitus position. 
Acquisition and analysis were performed using VividQ and EchoPac (GE Medical, 
Norway). All images were optimised with gain, compression, and dynamic range to 
enhance myocardial definition. Given time constraints during the trial we focussed on 
fewer images and outcome variables compared to Chapter 5. Apical 2- and 4-chamber 
views allowed the examination of LV end-diastolic (LVEDV) using the Simpson 
Biplane method. This facilitated the estimation of LV ejection fraction (EF).  Stroke 
volume (SV) was determined by subtracting LV end-systolic volume from LVEDV.  
 
LV diastolic filling was assessed using pulsed-wave Doppler echocardiographic 
recordings from the apical 4-chamber view. Specifically, spectral Doppler envelopes 
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characterized from a 4 mm sample volume allowed measurement of peak flow velocity 
of the early diastolic rapid filling E wave and peak flow velocity of the late diastolic 
filling wave due to atrial contraction (A). The ratio of E wave to A wave (E/A) was 
calculated.  The same apical view was used for tissue Doppler assessment of peak 
myocardial tissue velocities in the basal septum and basal LV lateral wall at the level 
of the mitral annulus as well as the basal RV lateral wall at the level of the tricuspid 
annulus.  Peak systolic (S’), peak early diastolic (E’) and peak late atrial diastolic (A’) 
myocardial velocities were recorded.  
 
Before exercise and at all measurement points post-exercise, arterial blood pressure 
was recorded using an automated sphygmomanometer (Dinamap, GE Medical, 
Wisconsin, USA).  Body mass was recorded using an electronic weighing scale 
(SECA, Germany). 
 
Statistical Analyses  
Statistical analysis was completed using IB SPSS 23.0 (SPSS, Chicargo, Illinois) 
software.  All data are reported as mean ± SD and statistical significance is set at P < 
0.05.   Two-way repeated measures ANOVA (time [3 levels] - PRE vs. 0 vs 1 h post-
exercise, intervention [two levels - RIPC vs. SHAM) was used to test the changes 
during the 160 km continues bike ride for the primary and secondary outcome 
parameters and whether these changes occur when exercise preceded by RIPC or 
SHAM.  When there was a significant main or interaction effect post-hoc analysis was 
used, using the Bonferroni test, to correct for multiple comparisons.  Repeated 
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measures t-test was used to analyse environmental and performance data associated 
with trial 1 vs. trail 2 as well as RIPC vs. SHAM trials.  
 
6.3. Results 
160 km Cycle Rides 
Eight participants completed both trials with a single participant unable to take part in 
the group cycle for trial 2. Seven cyclists completed both trials together with the final 
participant cycling with the group during trial one and then completing the second trial 
alone.  In this case, the exercise time and average heart rate was held constant between 
trial 1 and 2 but this resulted in a decrease in distance completed in the second trial due 
to lack of pacing support in a group setting.  Performance data and ambient conditions 
for the two trials are contained in Table 6.2 as well as a comparison between RIPC and 
SHAM trials. Whilst there are some small performance differences between trial 1 and 
2 it should be noted that average and maximal HR were similar between the two trials 
and there was little performance difference between RIPC and SHAM trials.     
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Table 6.2.  Performance data and ambient conditions between trial 1 and 2 as well 
as RIPC and SHAM trial for the 160 km cycle rides 
 
 
Pre=pre exercise sample, Ex=exercise samples, R=recovery samples, numbers are ng/L through  each 
component of the protocol 
 
Cardiac Biomarkers  
There was a significant main effect of trial (P = 0.001) with data for hs-cTnI lower in 
the RIPC trial compared to the SHAM trial (independent of time).  There was a 
significant main effect of time (P = 0.043) with hs-cTnI values initially rising during 
early recovery (Figure 6.1.).  There was a significant interaction (trial * time) effect (P 
 
TRIAL 1 TRIAL 2 P-
VALUE 
RIPC SHAM P-
VALUE 
TIME 
(HR:MIN) 
04:47 + 
0:5 
05:14 + 
0:19 
< 0.05 05:04 + 
0:17 
04:59 + 0:18 NS 
DISTANCE 
(KM) 
154 171 < 0.05 164 + 14 161 + 9 NS 
AVERAGE SPEED 
(KM.H-1) 
32 + 1 32 + 1 NS 32 + 1 32 + 1 NS 
MAXIMUM 
SPEED 
(KM.H-1) 
71 + 2 62 + 1 < 0.05 66 + 4 68 + 6 NS 
AVERAGE HR 
(BT.MIN-1) 
140 + 13 139 + 12 NS 139 + 11 140 + 13 NS 
MAXIMUM HR 
(BT.MIN-1) 
169 + 13 169 + 19 NS 169 + 17 169 + 14 NS 
ENERGY 
EXPENDED 
(CAL) 
3696 + 
322 
3844 + 
709 
NS 3827 + 
160 
3624 + 653 NS 
MIN 
TEMPERATURE 
(OC) 
16 16 NS 16 17 NS 
MAX 
TEMPERATURE 
(OC) 
17 18 NS 18 + 1 18 + 1 NS 
MEAN WIND 
SPEED 
(MPH) 
7 12 - 10 + 3 8 + 2 NS 
WIND DIRECTION 
 
W WNW - - - - 
RELATIVE 
HUMIDITY 
(%) 
64 64 - 64 64 NS 
BAROMETRIC 
PRESSURE 
(HPA) 
1011 1024 NS 1019 + 7 1016 + 7 NS 
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= 0.018) that facilitated pairwise comparison at POST-0H and POS-1H where hs-cTnI 
values were lower after the RIPC trial at both time points compared to SHAM (P < 
0.05, Fig 6.1a). The maximum concentrations of hs-cTnI occurred POST-0H (RIPC 26 
+ 15 ng/L vs. SHAM 59 + 32 ng/L; see Table 6.2).  Evidence of individual 
heterogeneity is worthy of note. In all PRE samples only one cyclist had an hs-cTnI 
value above the clinical cut-off for myocardial damage (RIPC trial) but his values 
reduced across the rest of the trial.  In post-exercise samples individual variability was 
again noted with a maximal value of 100 ng/L (SHAM trial).  Four (RIPC trial) and six 
(SHAM trial) cyclists presented hs-cTnI values above the cut-off for myocardial 
damage at POST-0H but in all but one case a reduction was noted at the subsequent 
POST-1H sample point.  In the other participant there was an increase in hs-cTnI at 
POST-1H (POST-0H 35 ng/L vs. POST-1H 82 ng/L).   
 
There was a significant main effect of intervention for NT-proBNP data with values in 
RIPC trial lower than in the SHAM trial (P = 0.001; Fig 6.1b); There was a significant 
main effect of time (P = 0.001) with values rising from PRE to post-exercise.  The 
interaction (trial * time) was also significant (P = 0.007) with pairwise post -hoc 
comparisons revealing lower NT-proBNP data at both POST-0H and POST-1H in the 
RIPC trial.  Maximal values for NT-proBNP occurred POST–0H for SHAM (RIPC 100 
+ 47 ng/L vs. SHAM 123 + 52 ng/L; Figure 6.1b: Table 6.2).   Although individual 
heterogeneity in NT-proBNP data was observed all participants values were below the 
clinical cut-off value with the highest (194 ng/L) observed at POST-1H in the SHAM 
trial.  This subject completed this trial alone and was the only participant to see his 
NT-proBNP value rise from POST-0H to POST-1H. 
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Figure 6.1. hs-cTnI (a) and NT-proBNP (b) values at PRE, POST-0H and POST-
1H exercise time points during both RIPC (open squares) and SHAM (solid 
circles) trials. 
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Cardiac function  
Table 6.3. Cardiac loading and rate changes at PRE, POST-0H & POST-1H time 
points during both RIPC and SHAM conditions in competitive cyclists in both 
trials (n=8, mean ± SD). 
 
Abbreviations: HR, Heart rate; SBP, Systolic Blood Pressure; DBP, Diastolic Blood Pressure; LVEDV, left 
ventricular end-diastolic wave 
 
There was no significant main effect (trial or time; both P>0.05) and no significant 
interaction effect for LVEDV (a surrogate of preload), HR, and blood pressure 
(P>0.05; Table 6.3).  
 
There were no significant main effects or interaction term for any index of LV systolic 
function (EF, SV and S’ [all wall segments]; P>005; see Table 6.4).  
  INTERVENTION P VALUES   
  PRE POST-0H POST-1H   
HR (BEATS/MIN)         
RIPC 63 ± 4 69 ± 7 64 ± 3  Trial  0.864 
SHAM 64 ± 6 70 ± 4 62 ± 4  Time 0.200 
     Trail x time  0.113 
SBP (MMHG)       
RIPC 124 ± 14 125 ± 10 119 ± 8  Trial  0.553 
SHAM 134 ± 9 125 ± 8 120 ± 7  Time 0.236 
     Trail x time  0.291 
DBP (MMHG)       
RIPC 71 ± 6 74 ± 10 71 ± 4  Trial   0.190 
SHAM 85 ± 8 72 ± 6 67 ± 9  Time 0.213 
     Trial x time 0.230 
LVEDV (ML)       
RIPC 146 ± 14 132 ± 18 130 ± 32  Trial 0.124 
SHAM 146 ± 16 136 ± 12 128 + 24  Time  0.164 
     Trial x time                 0.871 
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Table 6.4. Measure of left ventricular systolic function at PRE, POST-0H and 
POST-1H exercise time points during both RIPC and SHAM conditions in 
regionally competitive cyclists in both trials (n=8, mean + SD). 
 
Abbreviations: LV EF, left ventricle ejection fraction; SV, stoke volume; S, septal; LS, lateral septal. 
 
A main effect of time was evident for E (P<0.05), with peak inflow velocity dropping 
immediately post-exercise in both trials (Table 6.5).   There was no main effect of trial 
and no significant interaction term for E. Data for peak A flow velocity were not 
mediated by time, trial or interaction. There was a substantial drop in E/A ratio 
immediately post-exercise, which contributed to a main effect of time as well as a 
significant interaction effect.  Pairwise comparison of E/A data suggested a lower 
value at Post-0H in the RIPC trial compared to the SHAM trial with little difference at 
Post-1H.  There was no main effect of trial, time or interaction for LV septal or lateral 
wall E’ (P>0.05, Table4).  Data for peak LV septal or lateral wall A’ flow velocity 
were not mediated by time, trial or interaction.  
  
INTERVENTION P VALUES   
  
PRE POST-0H POST-1H  
 
LV EF (%)       
RIPC 
SHAM 
 
51 ± 15 
52 ± 11 
58 ± 14 
58 ± 12 
54 ± 16 
58 ± 19 
 Trial 
Time 
Trial x time    
0.289 
0.122 
0.452 
 
SV (ML) 
      
RIPC 72 + 22.7 79 + 16.1 79 + 21.1  Trial  0.927 
SHAM 76 + 16.7 75 + 13.8 74 + 27.2  Time 
Time x time 
0.663 
0.359 
LV SEPTAL   
S’ (M.S-1) 
RIPC 9 + 1 9 + 2 9 + 1  Trial  0.119 
SHAM 8 + 1 9 + 2  9 + 2   Time 0.911 
     Trial x time  0.709 
LV LATERAL WALL 
S’  
(M.S-1)  
RIPC 11 + 3.6 12 + 3.0 12 + 3.5  Trial  0.160 
SHAM 13 + 2.8 13 + 2.8 13 + 2.8  Time 0.149 
     Trial x time  0.454 
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Table 6.5. Measure of right ventricular systolic and diastolic data at PRE, POST-
0H and POST-1H exercise time points during both RIPC and SHAM conditions in 
regionally competitive cyclists in both trials (n=8, mean + SD) 
 
 
Abbreviations: LV E and LV A wave, Left ventricle, early (E) to late (A) wave; late diastolic filling; LV E/A, is 
the ratio of the early (E) to late (A) ventricular filling waves. Septal E’ and Septal A’; Septal early (E’) to late 
(A’); LV’ lateral E’ and A’, early (E’) and late (A’) lateral wall.    
 
  
  
INTERVENTION   P VALUES   
  
PRE POST-0H POST-1H   
LV E (m.s-1)       
RIPC 83 ± 8 69 ± 11 69 ± 13  Trial  0.165 
SHAM 82 ± 15 68 ± 16 71 ± 13  Time 0.035* 
     Trial x time 0.073 
LV A (m.s-1) 
RIPC 55 ± 10 60 ± 12 554 + 12  Trial  0.291 
SHAM 54 ± 8 66 ± 7 61 + 8  Time 0.115 
     Trial x time  0.0.72 
LV E/A       
RIPC 1.53 ± 0.26 1.34 ± 0.51 1.16 ± 0.30  Trial  0.058 
SHAM 1.57 ± 0.52 1.04 ± 0.24  1.23 ± 0.36   Time 0.047* 
     Trial x time  0.022* 
LV SEPTAL E’ 
(m.s-1) 
RIPC 12 ± 2 10 ± 4 10 ± 3  Trial  0.162 
SHAM 10 ± 3 10 ± 4  9 ± 3   Time 0.128 
     Trial x time  0.787 
LV  SEPTAL 
A’ (m.s-1) 
RIPC 9 ± 2 8 ± 2 10 ± 1  Trial  0.175 
SHAM 9 ± 1 10 ± 3  9 ± 2   Time 0.239 
     Trial x time  0.951 
LV LATERAL 
Wall E’ (m.s-1) 
RIPC 14 ± 4 13 ± 4 13 ± 4  Trial  0.824 
SHAM 13 ± 3 13 ± 3  13 ± 4   Time 0.981 
     Trial x time  0.975 
LV LATERAL 
Wall A’ (m.s-1) 
RIPC 9 ± 3 10 ± 2 
   
9 ± 3  Trial  0.593 
SHAM 9 ± 3 9 ± 2  9 ± 2   Time 0.958 
     Trial x time  0.363 
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Table 6.6. Measure of right ventricular systolic and diastolic data at PRE, POST-
0H and POST-1H exercise time points during both RIPC and SHAM conditions in 
regionally competitive cyclists in both trials (n=8, mean + SD). 
 
 
Abbreviations: RV S’, right ventricle septal; RV E’ and RV A’ waves, right ventricle early (E); to late (A)  
 
There was no significant main effects of time or trial and no significance interaction 
effect for RV free wall S’, E’ and A’ (P>0.05, Table 6.6).  
 
6.4. Discussion  
In the previous chapter we concluded that exposure to RIPC (versus SHAM) before 
exercise may reduce the hs-cTnI response to a subsequent laboratory-based, controlled 
60 min cycling exposure. This study extended the previous chapter by employing an 
exercise exposure of significantly greater volume that was more representative of a 
field-based cycling event.  The principal findings from the current study are: a) hs-cTnI 
was reduced after 160 km of cycling that followed exposure to RIPC compared to a 
  
INTERVENTION   P VALUES   
  
PRE POST-0H POST-1H   
RV FREE WALL S’ (m.s-1) 
      
RIPC 
11 ± 1 13 ± 3 13 ± 3  Trial  0.109 
SHAM 12 ± 2 13 ± 4 14 ± 4  Time 0.499 
     Trial x time 0.324 
RV  FREE WALL E’ (m.s-1) 
RIPC  13 + 2 9 + 3 11 + 5  Trial  0.852 
SHAM 11 + 3 12 + 3 10 + 2  Time 0.050 
     Trial x time 0.467 
RV  FREE WALL A’ (m.s-1) 
RIPC 11 + 3 14 + 4 15 + 3  Trial  0.203 
SHAM 13 + 3 15 + 4  15 + 3   Time 0.157 
     Trial x time  0.056 
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SHAM trial; (b) NT-proBNP was also lower following 160 km of cycling after RIPC 
compared to SHAM; and (c) cardiac function was relatively well preserved after a 160 
km cycle ride and post-exercise changes were not mediated by RIPC or SHAM.   
 
Cardiac Biomarkers  
Pre exercise levels of cTnI were similar in both trials and were at the same quantitative 
level as seen in previous chapters in that all but one subjects had hs-cTnI levels below 
clinical cut-off for myocardial infarction for week 2 (31 ng/L).  This suggests that the 
other participants presented for testing in an appropriate stage of recovery from 
previous prolonged exercise training bouts. The one subject that was above URL may 
not have been in a complete state of rest/recovery before the trial (may not have rested 
as requested between studies). In both trials hs-cTnI rose post-exercise with a drop-off 
toward baseline in early recovery (POST-1H).  This kinetic of response was consistent 
between individuals and similar in both RIPC and SHAM trials.  This is a very similar 
finding to a range of laboratory and field-based studies including those using cycling as 
an exercise stimulus (Scharhag et al., 2005; Middleton et al., 2008; Skadberg et al., 
2017).  The post-exercise levels of hs-cTnI were greater at POST-0H than in previous 
studies within this thesis, which may be as a result of between study differences in 
exercise volume as well as the fitness status of the participants (Shave et al., 2008).  
Specifically, the use of competitive cyclists and an exercise exposure that lasted for 5 
hours at optimal “race” pace helped to produce higher levels of hs-cTnI after both 
SHAM and RIPC trials compared to data observed in the previous chapter. This would 
support the concept that exercise duration or volume is more important in relation to 
exercise-associated elevations in cTn that exercise intensity (Dawson et al., 2003).  
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The most striking finding in relation to the hs-cTnI data was the significant attenuation 
of values observed after the RIPC trial compared to the SHAM trial.  We noted a 
significant main effect of trial as well as a significant time by trial interaction. This 
supports and extends the findings in the previous chapter and suggests that ischaemia 
(the effects of which are potentially offset via prior RIPC) may play some role in the 
hs-cTnI response to prolonged exercise. It should be noted that like the previous 
chapter the current data does not support the findings of Massaoudi et al. , (2013) who 
did not observe a mediating effect of RIPC on cTnI (or NT-proBNP). The 
contradictory nature of the between-study outcomes could be due to a number of 
factors; exercise mode, intensity, duration and volume; participant’s fitness status; 
RIPC exposure; or a combination of factors. 
 
The explanation for the lower hs-cTnI after exercise in the RIPC trial implicates 
ischaemia to some extent but the fact that hs-cTnI was still elevated over baseline in 
the RIPC suggest other mechanisms may be at play in both trials.  Whilst our current 
research study cannot directly implicate potential ischemic pathways that are altered by 
RIPC we make the following limited speculation.  Ischaemia has a number of direct 
and indirect effects on the cardiomyocyte that include a reduction in intracellular ATP 
an increase in protons and an upregulation in glycolysis (Piper et al., 2004) that 
together can negatively affect the Na/ Ca2+ pump which results in an increase in Ca2+ 
(Gateau-Roesch & Argaud, 2006).  Alongside a rise in reactive oxygen species (ROS) 
the increase in intracellular Ca2+ can lead to an opening of mitochondrial membrane 
pores therefore increasing membrane permeability called mitochondrial permeability 
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transition pores (mPTP).  If this happens in RIPC where ischaemia is followed by 
reperfusion and re-oxygenation, some level of protection against the development of 
mPTP is assumed. Cardiomyocyte protection occurs in the first few minutes of 
oxygenated reflow and it has been suggested that a range of pathways and mechanisms 
contribute to the protection of cellular integrity.  Possible pathways include the 
upregulation of the signalling protein kinase C (PKC).   When an inhibitor to PKC-ε is 
employed, cardiomyocyte protection is reduced (Murphy & Steebergen, 2008).  Jin et 
al., (2004) suggested that sphingosine 1 phosphate (S1K) may also have a protective 
role as an inhibition of S1K reduced the cardioprotective effects of RIPC in mice.  We 
can speculate that the increase in hs-cTnI observed in the SHAM trial was due to the 
lack of RIPC and the upregulation of signalling pathways that prevent or reduce 
ischemic damage and processes such as mPTP. Critically, the different mechanisms 
and their contributions involved in cardioprotection after RIPC remain unclear and 
therefore requires verification, likely in animal model studies.   
 
Although still to be confirmed, the rapid elevation and clearance of the cTn that occurs, 
as well as the quantities measured indicate reversible cell damage as opposed to 
irreversible cell death. There is a general agreement that the presence of elevated cTn 
is not an indication of irreversible damage (Shave et al., 2010) but likely reflects cTn 
release from the unbound “cytosolic” pool rather than contractile apparatus.  As well as 
a role for ischaemia, other mechanisms should be briefly noted as hs-cTnI did rise 
post-exercise after a SHAM procedure that would seem to rule out ischaemia as a lone 
mechanism.  There are a number of different non-ischemic mechanisms, such as a 
stunned myocardium, blebs or myocardial swelling buds (Kloner et al., 1974; Sage et 
al., 1988) and in specific studies environmental stressors such as heat (Whiticar et al., 
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2008) and high altitude influences (Boos 2013; Mellor et al 2013). It is speculated that 
these potential mechanisms could be related to a rise in reactive oxygen species (ROS) 
that is known to occur from the metabolic processes of aerobic prolonged exercise (Di 
Meo and Venditti 2001: Sahlin et al., 2010).  It is believed that elevated lipid cells 
membrane peroxidation may result in myocyte cell membrane damage or dysfunction 
(Ju 2001).    
 
These potential mechanisms require further study. Both the last chapter and this 
present study may be the first to indirectly show the role of ischaemia in exercise 
induced hs-cTnT and hs-cTnI but some caveats are important. Firstly, there was no 
evidence of ischaemia on post exercise ECG traces (associated with the 
echocardiogram) and secondly there were no other signs and symptoms of acute 
coronary syndromes.  The potential role of ischaemia still requires further clarification. 
 
The peak post-exercise hs-cTnI occurred at POST-0H but was quite heterogeneous 
between individuals.  This is also similar to past work (Middleton et al., 2007; Regwan 
et al., 2010; Vilela et al., 2014).  Some values were above clinical cut-offs for ACS 
(Thygesen et al., 2013) but the subject that had a hs-cTnI concentration 5 x the clinical 
cut-off criteria (100 ng/L at POST-0H) had one of the lowest hs-cTnI levels in the 
group by POST-1H.  In the absence of cardiac dysfunction, ECG changes associated 
with ACS and, any other signs and symptoms of cardiovascular disease we would 
suggest that the post-exercise elevation in hs-cTnI is likely of minimal clinical 
significance. 
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Unlike the previous chapter, NT-proBNP increased significantly post-exercise in both 
trials.  This corresponds with past endurance-exercise studies (Scharhag et al., 2008; 
Lippi et al., 2008; Scott et al., 2009; Tian et al., 2014). The rise of the biomarker may 
be associated with stretch of the atria and the hemodynamic overload associated with 
exercise. Hamasaki (2016) proposed in their extensive review that NT-proBNP release 
was linked primarily to exercise duration rather than intensity.  Neumayer et al., (2005) 
believed the elevation of NT-proBNP was a physiological endocrine response to 
mitigate against myocardial stress.  Hamasaki (2016) proposed that NT-proBNP 
release with endurance exercise may have cardio protective and growth regulatory 
effects on the myocardium.  A novel funding was that the NT-proBNP response to 
exercise was decreased after RIPC, despite the fact that in event and post event cardiac 
function data do not suggest different hemodynamic stress (and thus myocardial 
stretch) between trials. This phenomenon has not been described before and was not 
observed in the previous chapter.  Whether and how RIPC has some protective effect in 
terms of signalling pathways to NT-proBNP release is difficult to determine in the 
current research design and requires further research. 
 
Cardiac Function  
There were no meaningful post-exercise changes in LV or RV systolic function 
observed in either trials (RIPC or SHAM).  Consequently this data is in agreement with 
the findings of previous chapter and other empirical work (Goodman et al., 2001; Tian 
et al., 2014), but contrasts with others who have observed evidence of changes in left 
ventricular systolic function in a range of exercise settings (Upton, et al., 1994; Shave 
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et al., 2002; Middleton et al, 2006; Ostariz et al., 2013). This would suggest that 
cardiac functional integrity is well preserved after 160 km cycling and this possibly 
reflects the training status and nature of cycling (load supported) when compared to 
most evidence of cardiac fatigue that comes from ultra-endurance running (George et 
al., 2009; Scott et al., 2009). 
 
The transient decline in peak E diastolic flow velocity that occurred at POST-0H 
confirms similar data from the previous study and seems to be a highly consistent 
finding in both lab and field based work that has assessed diastolic function after 
endurance exercise (Middleton et al., 2007; Oxborough et al., 2010; Ostariz et al., 
2013).  Interestingly changes in diastolic flow parameters were not exactly matched by 
regional assessment of tissue velocities during diastole in either the LV or RV that is 
somewhat at odds with previous research (Williams et al., 2007).  Whilst the 
qualitative direction of change for E’ and A’ matched data for flow velocities the 
magnitude of change and low sample size may have contributed to a lack of statistical 
significance.  Changes in early diastolic filling velocities have been linked to a 
reduction in preload, alterations in heart rate and/or some intrinsic mechanism related 
to cardiomyocyte relaxation.  It is difficult to provide irrefutable evidence for any of 
these other than an increase in HR is usually accompanied by an increase in E which is 
not what has happened here (Giannaki et al., 2008).  At POST-0H there was a 
significant correlation between delta E and delta LVEDV (r = .49) partially suggesting 
a role for preload in the decline in early filling velocities. 
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 A link between cardiomyocyte damage and changes in LV/RV function, proposed by 
Dawson et al., (2003), is not supported here as the changes in hs-cTnI that were 
augmented in the SHAM trial were not matched by bigger changes in E.  This increase 
in the biomarkers and the manipulation by RIPC seen in this present study and the lack 
of a reduction in LV systolic function may indicate different mechanisms or the 
activation of these mechanisms in an order that facilitates protection of the 
myocardium.    Other intrinsic mechanisms such as altered intercellular Ca2+ handling 
are impossible to evaluate in the current research setting.  These areas require further 
investigation.  
 
Implications 
Based on the transient nature and quantity of the biomarkers observed post-exercise it 
is unlikely that the elevation of these biomarkers are indicative of long-term 
irreversible damage or dysfunction in the myocardium (Shave et al., 2010; La Gerche 
et al., 2012).  It is highly likely that post-exercise changes in cardiac biomarkers have 
no immediate clinical consequence, however, due care and consideration should always 
be given to an elevated hs-cTnI in any clinical assessment.  The evidence that RIPC did 
have an effect on two prominent cardiac biomarkers, that are well established for the 
diagnosis of myocardial infarction (hs-cTnI) and heart failure (NT-proBNP), should 
prompt further investigation employing a range of RIPC protocols, different exercise 
settings and/or different participant groups. 
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Limitations  
The relatively small sample size (N=8) has an impact on the generalisability of the 
findings.  The blood pressure (20 mmHg) employed in the SHAM trial made it 
challenging to adequately blind subjects to their treatment, and could influence the 
performance of participants. The combined use of manual and automatic pressure cuffs 
for RIPC may have provided some minor alterations in treatment exposure.    
 
6.5. Conclusion 
The use of RIPC prior to a 160 km cycle ride significantly reduced the magnitude of 
both hs-cTnI and NT-proBNP release post-exercise when compared to a SHAM trial.  
This suggests some putative role for ischaemia during exercise-induced changes in hs-
cTnI.  How RIPC mediates NT-proBNP data is not clear. There was no evidence of 
change in systolic cardiac function post-exercise in both trials.  The decline, post-
exercise, in early diastolic inflow (E) was consistent between trials but linkage between 
functional depression and biomarker elevation was not apparent.   
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Chapter 7: 
General Discussion  
 
7.1. Overview of Study Aims and Hypotheses 
At the beginning of the thesis and then is specific studies we stated the following 
hypotheses.  The outcome to these hypotheses is summarised in Table 7.1. This 
provides the brief backdrop to some generic issues worthy of discussion at this stage of 
the thesis 
 
STUDY1: Hypothesis 1: Running for 2 hours on a motorised treadmill at moderate 
intensity will reveal a rapid turnover of cTnI, using the new high sensitivity assay, and  
NT-proBNP in moderately active adults. 
STUDY 2: Hypothesis 2a: Cardiac biomarker responses to the same exercise bout 
employed in STUDY 1, are highly repeatable after a period of 7 days between exercise 
tests in the same participants.  
STUDY 2: Hypothesis 2b: Cardiac biomarker responses to the same exercise bout 
employed in STUDY 1, and Hypothesis 2a, will be highly repeatable after a period of 
12 weeks between the first and last exercise test in the same participants.  
STUDY 3: Hypothesis 3: Exercise-related changes in cTn, NT-proBNP and cardiac 
function will be attenuated when a 1-h strenuous cycle time trial exercise is preceded 
by RIPC in comparison to a time trial proceeded by a SHAM treatment. 
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STUDY 4: Hypothesis 4: Exercise-related changes in cTn, NT-proBNP and cardiac 
function will be attenuated when a 160 km cycle trial is preceded by RIPC in 
comparison to a time trial proceeded by a SHAM treatment.  
 
After reflection on the entire thesis, we identified the following overarching issues 
worthy of some comment within and between studies; 
 
Lab Versus Field Studies 
Many of the research studies to date (see meta-analysis by Shave et al., 2007) 
employed research designs with continuous but variable intensity exercise undertaken 
during competitive races in the “field”.  The two primary reasons for these types of 
study were; (1) easy access to well-motivated groups of compliant athletes, and (2) the 
ability to assess the impact of extremes of exercise prescription (e.g. Ironman 
Triathlons, 100 mile races, multi-day events). This approach provided a “rich” set of 
data and was the foundation of Shave’s meta-analysis and further narrative reviews 
(Oxborough et al., 2010).  
 
Despite positive aspects to this “living-lab” approach, there are limitations. The 
competitive nature of the events assessed meant that access to participants during the 
race was challenging and, therefore, blood collections only occurred pre- and post-race.  
Occasionally some extra blood samples were collected into early recovery (Scott et al., 
2009) but this was not the “norm”.  Based on the data generated from the landmark 
study of Middleton et al., (2007) there are serious concerns about the limited insight 
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provided by only two blood draws and biomarker analyses. Whilst informative, and 
certainly allowing often unremitting volumes of exercise to be studied, the 
preponderance of field-based studies places a significant challenge to our broader 
understanding and knowledge of exercise-related biomarker work. 
 
We choose to move our focus for the first three studies of this thesis from the field into 
controlled laboratory-based research designs to partially address the imbalance in 
previous research. Laboratory studies allow some element of replication and extension 
of the landmark laboratory-based treadmill study of Middleton et al., (2007) that 
pioneered multiple blood draws and was extended by other groups, notably in Spain 
(Legaz-Aresse et al., 2012) and Macau/China (Nie et al., 2012), to provide a better 
reflection of biomarker “kinetics”. The ability to take blood samples during exercise 
and into the recovery period was an important element of the laboratory-based studies 
in this thesis.   
 
Interestingly, despite the adaption of multiple blood draws with and after exercise in 
our laboratory-based studies the positive biomarker response (specifically cTn) and the 
magnitude of any individual rise in cTn was very limited.  This likely reflects a 
combination of; (a) a low exercise dose, (b) a less trained group of participants, (c) a  
high assay detection limit in studies 1 and 2, and (d) all of the previous points acting 
synergistically.  Points (a) and (b) are largely the limitations of laboratory-based 
studies that must be balances against the limitations of field work already noted. 
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To confirm the interplay between exercise and RIPC from study 3 we made the 
decision to move back to the “field” for study 4. This facilitated a much greater 
exercise dose and this illuminated a clearer role for ischaemia.  Much larger cohort and 
individual cTn responses were observed in both trials of study 4. This highlights the 
value of exercise volume in cardiac biomarker studies.      
 
In summary, the first three studies attempted to take advantage of the strengths of using 
a laboratory environment in the belief that it allowed for more precise conclusions 
about biomarker responses during controlled exercise exposure.  Although a valid 
approach prolonged exercise in the laboratory does bring its own challenges.  Feedback 
from the participants alluded to the difficulty of exercising in an environment when it 
is not the participant’s natural competitive or training environment and thus exercise 
volume was reduced. The use of a field-based environment in the final study 
demonstrated a greater biomarker response. These studies do not suggest that 
laboratory or field based studies have distinctive benefits and limitations and should be 
combined, as appropriate, in on-going research.  
 
Fitness of the Participants 
This issue was raised briefly in the last section but is worth considering separately.  
Specifically this PhD contained 2 studies with less-well trained participants (Chapter 3 
and 4) as well as 2 studies with well-trained cyclists (RIPC work in Chapter 5 and 6). 
In previous research there has generally been a focus on highly trained endurance 
athletes (e.g. Scott et al., 2009) although there is ample data from “charity” runners at 
events like Marathons (Shave et al., 2005; Fortescue et al., 2007).  Fortescue et al., 
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(2007) did note, in a large and diverse sample completing the Boston Marathon, that 
inexperience and younger age were the strongest predictors of cTn elevation.   
 
Whilst “fitness” is a difficult construct to measure or report accurately, and different 
studies have only attempted self-report descriptive indices (Fortescue et al., 2007), it is 
logical that differences in fitness status should be considered as relevant for biomarker 
studies.  We know that fitness status markedly effects cardiac structure, function and 
electrical activity so it may be postulated to also influence the ability to withstand 
cardiomyocyte insult in prolonged exercise exposures (George et al., 2011). Unpicking 
participant fitness from the exercise dose within most field studies is also extremely 
difficult.  Despite this, and again with knowledge of changes in assay detection limits, 
we would tentatively support the notion that less well-trained participants, undertaking 
smaller bouts of exercise, are likely to show smaller changes in cardiac biomarkers 
post-exercise. 
 
The biggest changes in cTn and NT-proBNP came in study 4 which combined both the 
high training status of the athletes with the biggest exercise dose in this thesis.  The 
cTn and NT-proBNP data were substantially higher in this study than all the 3 previous 
datasets. Whether this is exercise volume or fitness status cannot be explicitly unpicked 
post hoc.  It is likely a combination of these factors such that these athletes have the 
ability to hold an elevated exercise intensity over a prolonged period we believe would 
contributed to continued hemodynamic stress on the myocardium that resulted in cTn 
and NT-proBNP elevations post-exercise.     
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In summary, in our studies we noted that cTn responses were more common in more 
experienced/trained participants completing more prolonged exercise, compared to less 
experienced participants doing less work. The issue of interpreting this data is that it is 
quite difficult to un-pick participant experience from exercise volume (intensity) and 
also biomarker detection limits employed (which varied between studies).  Whilst our 
work agrees with some past work it disagrees with other studies (e.g. Fortescue et al., 
2007; Eijsvogels et al., 2010) and this suggests that further study is required to evaluate 
these specific issues on biomarker response to exercise.  
 
The use of Different cTn assays and Detection Levels 
To lower detection levels we used the new hs-cTnI and hs-cTnT which are both widely 
used within a clinical setting for the diagnosis of AMI and other diseases related to 
cardiac muscle injury (Westwood., 2015).  There is speculative evidence that a reason 
for differences in exercise detection response may be as a result of the differences in 
molecular weights between hs-cTnI (24 kDa) and hs-cTnT (35.4 kDa) (Eijsvogels et 
al., 2010) as well as differences in assay detection levels (Shave et al., 2010).   With 
hs-assays it may be that inter-biomarker differences may be reduced. 
 
For the first 2 studies in this PhD hs-cTnI was the cardiac biomarker of choice 
(alongside NT-proBNP). These showed only very modest and infrequent elevations in 
hs-cTnI above the assay detection limit of 20 ng/L (study 1 POST-1H 22 ng/L 
increased by POST-3H to 24 ng/L, study 2 POST-1H 25 ng/L increased by POST-3H 
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to 38 ng/L).   This detection limit is lower than old 1-4th generation assays but still too 
high for the combination of athlete group and limited exercise exposure.  
 
Study 3 in this PhD employed the hs-cTnT (rather than hs-cTnI used for studies 1 and 
2) following the same blood draw analyses times as study 1 and study 2 (immediately 
post exercise and 1 h and 3h). The use of this assay hs-cTnT assay allowed the lower 
end to be “opened-up” and thus to report the assay to a much lower detection threshold  
(3 ng/L).  Changes in cTn values (higher in the SHAM trial) included POST-0H 20 
ng/L that increased by POST-1H to 22 ng/L and POST-3H to 25 ng/L.  These data are 
still low and similar to the small number of positives in studies 1 and 2 but the overall 
kinetics were much easier to observe in all participants.  Despite this the low 
magnitude and rapid clearance of cTn values did not indicate irreversible changes to 
the myocardium as would be observed after an AMI.   
 
Study 4 went back to using hs-cTnI now that we could lower the detection level on this 
assay in line with study 3.  cTn values were higher in this study (maximum 
concentration occurred POST-0H (RIPC 26 ng/L vs. SHAM 59 ng/L) all but one case 
showed reduction at the subsequent POST-1H sample point but this likely represented 
the longer exercise exposure and training status as much as the specific assay.  Again 
the limited magnitude and rapid turnover of cTn does not indicate, match the kinetics 
observed in AMI. 
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In summary, the cTn detection threshold used in our studies for cTn varied but were 
still lower that older assays.  That said opening up the assay capabilities provided extra 
insight in low exercise-dose studies.  These assays should be used in exercise-
biomarker studies moving forward.  
 
Mechanisms and evidence for (ir)reversible cardiomyocyte damage with exercise. 
The last 2 chapters in this PhD employed echocardiography alongside biomarkers in an 
attempt to link changes in cardiac function to biomarker appearance. Studies 3 and 4 
did not show changes in LV systolic function which is in agreement with many other 
studies that have employed 1-5 hr of endurance exercise exposure (Oxborough et al., 
2012).  A study that employed cycling for 50 – 80 min to exhaustion at anaerobic 
threshold showed no change to cardiac function (Palatini et al., 1994).  This would 
indicate that systolic function is preserved during this type of exercise exposure.   
Changes in diastolic function post-exercise in study 3 and 4 were generally of a small 
magnitude, recovered quickly and were not mediated by RIPC and SHAM.  Thus, these 
changes had limited clinical significance and were not aligned with any biomarker 
changes.  A post-exercise, transient decline in diastolic function has been postulated to 
be due to a decrease in preload, ischaemia and damage, and/or other intrinsic processes 
(Oxborough et al., 2010).  This study was not able to provide irrefutable evidence of 
the role ischaemia as a key precursor for post-exercise changes in diastolic function as 
the effect was similar in both RIPC and SHAM trials.  
 
Whilst studies 1 and 2 did not point to specific mechanisms underpinning cardiac 
biomarker release the data, in totality, did not point to irreversible cardiac insult. 
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Studies 3 and 4 demonstrated a reduction in cTn levels after the RIPC test, compared to 
the SHAM trial, and this indicates that ischaemia is potentially part of the mechanistic 
cascade mediating the elevation of cTn during prolonged exercise. The evidence that 
cTn is also elevated in the SHAM trial indicates that the kinetics of cTn will be 
complex and will most probably be associated with a number of interrelated 
mechanisms. The idea of disproportionate functional change to the RV and elevated hs-
cTn and NT-proBNP with little or no change to the LV is in line with La Gerche et al., 
(2014). Although there is disparity with the mechanism of remodelling reactive oxygen 
species has been linked as a potential precursor (Schiattarella (2017).  Future studies 
will need to evaluate a number of mechanisms related to exercise associated changes in 
a range of different biomarkers.  Whilst it is still open to debate whether the release of 
cTn following exercise irrefutably reflects reversible or irreversible cardiac damage. 
The weight of evidence would support reversible and minor (sub-clinical) insults to 
cardiomyocytes.  This is supported by: 
1) Small magnitude of release, and 
2) Limited time-period for elevation. Clinically associated elevations has shown 
that cTn levels in the blood have high levels of cTn above URL and can last for 
21 days, whilst exercise associated elevations are lower and return below URL 
within 24 hours.  
3) Whilst a link between cardiomyocyte damage and cardiac function change was 
proposed by Dawson et al., (2003) this was not supported during this thesis.  
4) No other clinical signs and symptoms were observed in any trial, 
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5) Repeatability (whilst not elegantly supported) does suggest a physiological 
stimulus. 
 
Despite all of these statements there is still a need for due care and attention to any 
evidence of elevated cTn or NT-proBNP in a post-exercise setting until a range of 
investigations reduces the risk of a cardiac event. 
 
 97 
 
Table 7.1. Overview of individual study aims
Study title Chapter Hypotheses’  Results Conclusion  
Is there a rapid turnover 
of hs-cTnI and NT-
proBNP during and after 
2 h of prolonged 
moderate intensity 
exercise in healthy active 
individuals? 
 
Chapter 3 STUDY1: running for 2 hours on a motorised 
treadmill at moderate intensity will reveal a 
rapid turnover of cTnI, using the new high 
sensitivity assay, and NT-proBNP in 
moderately active adults. 
 
For the first study hs-cTnI was the cardiac biomarker of choice 
(alongside NT-proBNP). These showed only very modest and 
infrequent elevations in hs-cTnI above the assay detection limit 
of 20 ng/L (study  
 
 
In conclusion, moderate intensity prolonged running 
in healthy males resulted in a limited release of cTn 
(as detected by a new hs assay) as well as a 
significant, and exercise-duration dependent 
elevation in NT-proBNP.  The rapid elevation and 
removal during early recovery suggest these changes 
have limited clinical relevance and possibly reflect 
normal physiological processes. 
The repeatability of the 
hs-cTnI and NT-proBNP 
response to a 2 hr bout of 
prolonged moderate 
intensity running. 
Chapter 4 STUDY2a: Cardiac biomarker responses to 
the same exercise bout employed in STUDY 
1, are highly repeatable after a period of 7 
days between exercise tests in the same 
participants.  
 
 
Detectable hs-cTnI was identified in the same single runner in 
Week 0 and Week 1 trials and for the remaining 7 participants 
no detectable hs-cTnI was observed in either runs – suggestive 
of gross levels of repeatability [responders vs. non-
responders], 
 
 
Three similar bouts of prolonged treadmill running 
in healthy untrained males in weeks 0, 1 and 12 
resulted in a limited (gross level) repeatable cTnI 
response, with no real evidence of a repeat bout 
effect.    
The impact of remote 
ischemic preconditioning 
on cardiac biomarkers 
and functional response 
to endurance exercise 
 
Chapter 5 STUDY 3: Hypothesis 3: Exercise-related 
changes in cTn, NT-proBNP and cardiac 
function will be attenuated when a 1-h 
strenuous cycle time trial exercise is preceded 
by RIPC in comparison to a time trial 
proceeded by a SHAM treatment. 
 
Absolute hs-cTnT levels were lower after RIPC than SHAM 
across all time points post-exercise (main effect for trial: P < 
0.05), but there was no main effect of time or time-by-trial 
interaction (both P > 0.05). Maximal values for hs-cTnT 
occurred POST-3H (RIPC: 20 ± 9 ng/L vs. SHAM: 25 ± 8 
ng/L, P = 0.08). No main effect of time, trial or time-by-trial 
interaction was observed for NT-proBNP (all P > 0.05). 
 
Reduced serum hs-cTnT values were observed after 
a 60 minute cycling TT that was preceded by RIPC 
when compared to a SHAM protocol. This provides 
the first, indirect, evidence that ischaemia is 
implicated as a mechanism in changes in hs-cTnT 
post-exercise. 
The impact of remote 
ischemic preconditioning 
(RIPC) on the cardiac 
biomarker and cardiac 
functional response to a 
160 km cycle ride. 
Chapter 6 STUDY 4: Hypothesis 4: Exercise-related 
changes in cTn, NT-proBNP and cardiac 
function will be attenuated when a 160 km 
cycle trial is preceded by RIPC in comparison 
to a time trial proceeded by a SHAM 
treatment. 
 
There was a significant main effect of trial (P = 0.001) with 
data for hs-cTnI lower in the RIPC trial compared to the 
SHAM trial (independent of time).  There was a significant 
main effect of time (P = 0.043) with hs-cTnI values initially 
rising during early recovery.  There was a significant 
interaction (trial * time) effect (P = 0.018) that facilitated 
pairwise comparison at POST-0H and POS-1H where hs-cTnI 
values were lower after the RIPC trial at both time points 
compared to SHAM (P < 0.05). 
 
 The use of RIPC prior to a 160 km cycle ride 
significantly reduced the magnitude of both hs-cTnI 
and NT-proBNP release post-exercise when 
compared to a SHAM trial.  This suggests some 
putative role for ischaemia during exercise-induced 
changes in hs-cTnI 
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7.3. Future Research Direction  
Continued work is required to further our understanding of the mechanisms involved in 
cTn release during exercise.  The role of the myocyte plasma membrane could be a 
plausible place to begin to look at this in animal models. 
 
There is still a need to improve our understanding of exercise modality, participant’s  
fitness and environmental conditions.  Without better management of these variables it 
will be a challenge to further develop our understanding of responders and non-
responders (those that release cTn and those that do not).  This present study and many 
other research groups are showing that we have responders and non-responders during 
prolonged exercise.  There is a need to identify if non-responders do become responders 
after long-term training.  This could be achieved with the aid of a longitudinal 
investigation(s) on the impact of repeat bouts of prolonged exercise working with large 
sample size of high performing young and veteran endurance athletes to develop our 
understanding of responders and non-responders.     
 
7.4. Conclusion 
For this dissertation, I tested 6 hypotheses: 1) The running for 2 hours on a motorised 
treadmill at moderate intensity will reveal a rapid turnover of cTnI, using the new high 
sensitivity assay, for cTnI and NT-proBNP, REJECTED; 2) Cardiac biomarker 
responses are highly repeatable after 7 days, ACCEPTED; 3) Cardiac biomarker 
responses will be highly repeatable after 12 weeks, REJECTED; 4) Exercise-related 
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changes in cTn, NT-proBNP and cardiac function can be attenuated when 1-h strenuous 
cycle exercise is preceded by RIPC, ACCEPTED; 5) Higher and more divergent 
response in hs-cTnI, NT-proBNP after a 160 km cycle ride (c. 6 hr) preceded by SHAM 
as opposed to RIPC, ACCEPTED; 6) Indices of cardiac function after a 160 km cycle 
ride (c. 6 hr) preceded by SHAM as opposed to RIPC, – REJECTED.
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Appendix 1. 
 
Consent, Health Questionnaire, Participant Information and Risk Assessment forms   
 
 
The examples of the consent / assent forms given below are a minimum 
requirement which are suitable for most studies but may need alterations 
to be commensurate with individual study requirements. The participant is 
consenting to everything described in the text of the participant 
information sheet.  
 
For some studies a fuller itemised consent form may be needed to cover 
other important issues especially where additional elements are optional 
for the participant for example: 
 
 Additional invasive tests 
 Additional questionnaires, interviews or focus groups with sub-
samples of the study population 
 Consent to the use of audio/video-taping 
 Consent to the use of verbatim quotes or photographs 
 Transfer of data to countries outside of the EEA  
 Consent to the removal and storage of human tissue samples for 
future, undefined research 
 
Applicants should not that where a study involves the participation of 
children under the age of 16, parental consent should always be sought 
and, in the case of medical research or other invasive studies, parental 
 
CONSENT / ASSENT FORMS 
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consent should be sought from young people up to the age of 18. For social 
science based research young people aged 16 years and older are generally 
capable of giving their own consent; however as a research you will need to assess 
the individual’s capacity to consent, depending on their maturity and 
understanding. Where researchers are recruiting young people aged 16 – 18 years 
old without parental consent they should, where appropriate, encourage the young 
person to inform their parent or guardian of their participation. 
 
Where the proposed study involves the removal, storage or use of human 
tissue samples relevant information should be included in the participant 
information sheet and explicit consent for the removal, storage and / or 
use of the tissue samples sought in the consent form. Where applicable the 
explicit consent for the following should also be sought: 
 
 Genetic testing 
 Storage for future research (generic consent) 
 Use for commercial research 
 
Where a study involves the administration of a questionnaire or survey a 
signed record of consent is not required for completion of the 
questionnaire/survey as long as it is made clear in the information sheet 
that completion of the questionnaire/survey is voluntary. Under these 
circumstances return of the completed questionnaire is taken as implied 
consent.  
 
In such cases the REC would expect a statement to be included at the start 
of the questionnaire/survey where the respondent confirms that they have 
read the participant information sheet and are happy to complete the 
questionnaire. 
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Participation in any other interventions within the same study eg 
interviews, focus groups must be supported by obtaining appropriate written 
consent. 
 
Signatories to the consent should be those who are involved in the consent 
process eg the participant (or guardian/carer), the researcher or his/her 
representative delegated to take consent.  
 
Where a consent form is to be signed by a participant at home and returned 
by mail to the researcher 2 copies should be provided both of which are 
returned and countersigned by the researcher and one copy posted back to 
the participant.  
 
All consent forms must include the logo of the lead and any other 
participating institutions. All consent forms should be version dated in 
the header/footer to ensure that the most recent approved version is used. 
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EXERCISE-INDUCED CARDIAC BIOMARKER RELEASE: REVERSIBLE OR IRREVERSIBLE 
CARDIAC DAMAGE? 
 
Mark Benson – Research Institute of Sport & Exercise Sciences 
 
 
1. I confirm that I have read and understand the information 
provided for the above study. I have had the opportunity to consider 
the information, ask questions and have had these answered 
satisfactorily 
 
2. I understand that my participation is voluntary and that I am 
free to withdraw at any time, without giving a reason and that this 
will not affect my legal rights. 
 
3. I understand that any personal information collected during the 
study will be anonymised and remain confidential 
 
4. I agree to take part in the above study  
 
 
Name of Participant   Date    Signature 
 
 
Name of Researcher   Date   Signature 
 
 
LIVERPOOL JOHN MOORES UNIVERSITY 
CONSENT FORM 
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Name of Person taking consent Date   Signature 
(if different from researcher) 
 
Note: When completed 1 copy for participant and 1 copy for researcher  
Researchers details  
 
Mark Benson BSc (Hons), MSc, MPhil  
Research Institute for Sport and Exercise Sciences 
Tom Reilly Building 
Liverpool John Moores University 
L3 2ET 
benson@bryntirion.co.uk 
m.benson@ljmu.ac.uk 
mobile: 07539009647 
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HEALTH and TRAINING QUESTIONNAIRE  
 
The impact of ischemic preconditioning (IPC) on the 
cardiac biomarker response to endurance exercise 
The initial part of the questionnaire is to record any current or recent (last 2 weeks) 
self-report indications of ill health.  This question (only) will be repeated before all 
endurance exercise bouts to check you have not been ill during the last 2 weeks as 
this could affect the results of the study.   
 
Section one: Health Screen              (circle answer) 
 
1. Have you felt generally unwell within the last 2 weeks?   Yes No 
If yes, please specify _________________________________________________ 
 
2. Have you taken any prescription or non-prescription medication because of signs and 
symptoms of ill-health within the last 2 weeks    Yes No 
If yes, please state what medication you have taken _________________________  
3. Have you taken any days off work due to ill-health in the last 2 weeks  Yes No 
If yes, please specify _________________________________________________ 
4. Have you missed any training due to ill-health in the last 2 weeks  Yes No      
If yes, please specify _________________________________________________ 
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Section two: Personal Information   
 
5. Name:        
 
6. DOB:    Age: 
 
7. Height:    Weight:  
 
8. Address  
 
 
 
 
9. Telephone number: 
 
 Home:        
 
 Mobile:       
 
10. Email:        
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Section three: Medical History (adapted from PARQ)       (circle answer) 
11. Has your doctor ever said that you have had a heart condition?   Yes No 
 
If yes, please give details, including dates ________________________________ 
________________________________________________________________________
____________________________________________________________ 
 
12. Have you ever experienced pains in your chest?     Yes No 
 
If so, please give details, including what you were doing at the time ___________ 
________________________________________________________________________
____________________________________________________________ 
    
13. Do you ever faint or suffer from severe dizziness?   Yes No 
 
If so, please give details, including what you were doing at the time ___________ 
________________________________________________________________________
____________________________________________________________ 
 
14. Has a doctor ever said your blood pressure was too high?  Yes No 
If so, please give any details you can ____________________________________ 
   __________________________________________________________________ 
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15. Has a doctor ever told you that you had a joint or bone problem that might be 
exaggerated or aggravated by exercise?      Yes No 
If so, please give details, 
________________________________________________________________________
____________________________________________________________ 
 
16. Is there any good physical reason, not mentioned here why you should not take 
part in this physical activity challenge?     Yes No 
If so, please give details, 
________________________________________________________________________
____________________________________________________________ 
 
17.  Do you suffer from any medical condition that hasn’t been mentioned in the  
previous questions?        Yes No 
If so, please give details, 
________________________________________________________________________
____________________________________________________________ 
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18. Has any member of you close family (siblings, parents, grandparents) suffered 
from early onset cardiovascular disease (before 45 years of age in men and 55 in 
women)?         Yes No 
If so, please give details, 
________________________________________________________________________
____________________________________________________________ 
 
Section Four: Training, Competition and Lifestyle 
19. What is your highest level of competitive performance/achievement?      
Please provide a brief description? 
________________________________________________________________ 
________________________________________________________________ 
 
20. How long (years) have you been competing at this level? 
________________________________________________________________ 
________________________________________________________________ 
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21. Do you smoke?         Yes No 
What do you smoke (please circle)  cigarettes  cigars           pipe 
If yes,  
How long have you smoked for? ______________________________  
How many per day? ________________________________________ 
 
Have you ever smoked?        Yes No If 
yes,  
When did you smoke? ______________________________________ 
How many per day? ________________________________________ 
 
22. Do you currently follow any specific diet restrictions (e.g. gluten free, 
vegetarian)?        Yes No 
If yes please provide details 
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23. Do you take any dietary supplements?     Yes No 
If yes, please specify what you take and the frequency ______________________ 
__________________________________________________________________ 
 
24. What is your current training load (can you provide details of number of sessions,    
type of sessions, duration and intensity of sessions)? 
Monday _________________________________________________________ 
      ________________________________________________________________ 
 
Tuesday _________________________________________________________ 
      ________________________________________________________________ 
 
Wednesday_______________________________________________________ 
      ________________________________________________________________ 
 
Thursday__________________________________________________________ 
      ________________________________________________________________ 
 
Friday_____________________________________________________________ 
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      ________________________________________________________________ 
 
Saturday__________________________________________________________ 
      ________________________________________________________________ 
 
Sunday____________________________________________________________ 
      ________________________________________________________________ 
 
25. How long (months, years) have you been training at this level? 
      ________________________________________________________________ 
      ________________________________________________________________ 
 
26. Please detail any further information you would like to tell us ________________ 
_____________________________________________________________________ 
_____________________________________________________________________ 
_____________________________________________________________________ 
_____________________________________________________________________  
 
Participant signature: 
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Thank you for completing this questionnaire 
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Title of Project: EXERCISE-INDUCED CARDIAC BIOMARKER RELEASE: REVERSIBLE 
OR IRREVERSIBLE CARDIAC DAMAGE? 
 
Mark Benson – Research Institute of Sport & Exercise Sciences 
 
Introduction  
You are being invited to take part in a research study. Before you decide 
it is important that you understand why the research is being done and 
what it involves. Please take time to read the following information. Ask 
us if there is anything that is not clear or if you would like more 
information. Take time to decide if you want to take part or not. 
 
1. What is the purpose of the study? 
 
The purpose of the following studies is to contribute new data to the on-
going debate about the clinical relevance of exercise-induced release of 
cardiac biomarkers into the blood and whether this reflects reversible or 
irreversible damage to the heart of humans during and after prolonged 
exercise. These issues require further exploration to inform athletes, 
coaches, scientists and clinicians about the cardiovascular risks and 
benefits of engaging in prolonged and strenuous exercise. 
 
LIVERPOOL JOHN MOORES UNIVERSITY 
PARTICIPANT INFORMATION SHEET 
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2. Do I have to take part? 
 
No. It is up to you to decide whether or not to take part. If you do you 
will be given this information sheet and asked to sign a consent form. You 
are still free to withdraw at any time and without giving a reason. A 
decision to withdraw will not affect your rights/any future 
treatment/service you receive.”  
 
3. What happens if I take part in test 1 but become ill before one of the 
others tests?  
All participants will be screened (self-report signs and symptoms) for 
illness prior to all exercise bouts. If you are feeling unwell or have 
very recently (within last 2 weeks) been ill the test(s) will not commence 
on that day. To assess current or recent ill health we will ask you if you 
have had to have time off work/training, you recently took or are currently 
taking medication and you have a general feeling(s) of ill-health.  
4. Is there any exclusion criteria? 
Yes, one or more from the list below:  
a. Early (close male relatives under 45 years and close female 
relatives under 55 years of age) family history of 
cardiovascular disease 
b. Current musculoskeletal injury  
c. Younger than 18 or older than 45 years 
d. Not able to complete 2 hour running at 70 to 80% max running 
speed 
e. Self report current or recent (last 2 weeks) ill health 
i. general feeling of ill health 
ii. use of medication  
iii. having to take days off work or training    
f. currently training for a marathon 
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g.  
5. What will happen to me if I take part? 
 
The study will involve visiting the Sports Science laboratories at LJMU 
on a number of occasions after you have read this form, asked any questions 
and provided a written informed consent form. The testing sessions will 
involve: 
 Initially we will measure your cardiorespiratory fitness and anaerobic 
threshold on a treadmill (V̇̇̇̇O2max tests). This is a graded intensity 
test. During these tests you will be required to exercise to exhaustion 
whilst wearing a mouthpiece that will monitor how much oxygen you use 
during exercise. You will also be asked to wear a heart rate monitor. 
This trial should last about 20 minutes.  
 After this initial trial you will be asked to complete 3 endurance 
trials. This will mean a total of four visits to the laboratories.  In 
each of the endurance trials you will exercise for 120 min at 70 to 80% 
of peak running speed that will be determined from the initial maximal 
treadmill test.  
 For all tests, you will arrive at the lab in the morning (9 -10 am) 
after a light breakfast.   
 Before exercising you will undergo a cardiac scan, have your urine 
osmolality assessed, be weighed and have your blood pressure taken. You 
will have your skin temperature recorded, your core temperature 
assessed, using an aural probe that is placed just inside the outer 
ear, and a heart rate monitor fitted. A small needle will be put in a 
vein in your arm and left there for the duration of the exercise so 
that a total of 7 blood samples of 5 ml can be collected (total blood 
withdrawn is 35 ml).  This approach called “cannulation” means we don’t 
have to keep putting needles in to your arm every time we need to take 
a blood sample. Thirty-five ml represents a small amount of blood 
(equivalent to 1/4 of a small wine glass) and the use of the 
cannula will reduce the potential for bruising from repeated 
needle entries.  The insertion and maintenance of the venous 
cannula will be performed by qualified staff.   
 During exercise we will continuously measure heart rate, blood pressure, 
oxygen uptake, core and skin temperature.   
 Upon completion of the exercise protocol the same data collection 
procedures taken at rest will be completed immediately, 1 and 3 hours 
post-exercise. Please note that on the days you undertake the endurance 
trials you will be in the laboratories for the morning during which you 
will complete the endurance trial and the pre, during-exercise, post 
and 1 hr post blood samples will be taken. You are then free to leave 
but you will need to return briefly to the laboratories in the afternoon 
to provide a 3 hr post-exercise blood sample. The researcher looking 
after you will let you know the exact time you need to return on the 
day (see timeline below for exercise and blood samples)  
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6. Are there any risks / benefits involved? 
 
The subjects will wear a safety harness during the max tests as there may 
be a risk of falling during the max test and gloves and lab coats will be 
worn during the blood collection process to reduce the chances of 
infection. 
 
There is a small risk of infection due to a needle/cannula being used to 
take blood samples. This may also result in bruising at the site of needle 
insertion. Running may result in a level of muscle damage/soreness if the 
athlete is unaccustomed to the intensity and/or duration of the exercise. 
This can last between 24 and 72 hours.   
 
You will gain valuable information on your current state of fitness, the 
efficacy of your training regime and useful insights into your responses 
to prolonged running.  Knowledge of your own physiological responses to 
exercise over longer distance will be useful in your preparation for 
competition (or training).       
 
 
7. Will my taking part in the study be kept confidential? 
 
Your participation and all your data will be treated confidentially. 
 
If you have any questions relating to any of the techniques used during 
the research study please feel free to contact me to discuss this further. 
Participation in this research study is voluntary and you are free to 
withdraw at any time without prior explanation.  
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Mark Benson MSc 
Research Institute for Sport and Exercise Sciences 
Tom Reilly Building 
Liverpool John Moores University 
L3 2ET 
m.benson@ljmu.ac.uk  
mobile: 07539009647
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Generic Risk Assessment  
New 
 
 
Building……… Tom Reilly Building                 School/Service Department…Sports Science     Location…… Human Performance 
Laboratory 
 
Activity……… Research testing ………………………………………….    Date of Risk Assessment…………16/04/2016……………………………… 
 
Assessment carried out by…Mark Benson ….   Signed……………………………………….. 
 
Persons consulted during the Risk Assessment Professor Keith George and Andrew Hulton (Technician) 
STEP 1 
What are the Hazards? 
STEP 2  
Who might be harmed and 
how? 
STEP 3 (a) 
What are you already doing? 
STEP 3 (b) 
What further action is 
needed? 
STEP 4 
How will you put the assessment 
into action? 
Spot hazards by 
 Walking around the 
workplace 
 Speaking to employees 
Identify groups of people. 
Staff and students are 
obvious, but please 
remember 
 Some staff/students 
have particular needs 
What is already in place to 
reduce the likelihood of harm, or 
to make any harm less serious. 
 
 
 
Compare what you are 
already doing with good 
practice.  If there is a gap, 
please list what needs to be 
done. 
 
Please remember to prioritise.  
Deal with the hazards that are 
high risk and have serious 
consequences first. 
 
 
Assessment Number:………………… 
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 Checking manufacturers 
instructions 
 
 
- Venipuncture injury 
(including bruising 
around the sample 
site) 
 
- Infection from blood 
sample or sampling 
procedure 
 
- Muscular soreness 
from exercise  
 
- Dehydration/heat 
injury from prolonged 
exercise  
 People who may not 
be present all the 
time 
 Members of the 
public 
 How your work 
affects others if you 
share a workplace 
 
 
Subjects  
- All of points 
raised in STEP 1 
 
Researchers  
- Infection (see 
STEP 1) 
- All personnel 
involved with 
venepuncture and 
handling blood 
samples are fully 
trained. 
 
- Subjects will be 
fully familiarised 
with exercise. 
 
- A cut-off core 
temperature of 
39.5oC will be 
adhered to and 
water/fluids will 
be allowed ad 
libitum 
 
- No further 
(new) action is 
required. 
 
- These are 
points of good 
practice that 
will be adopted 
during the 
study. 
 
Action by 
whom 
 
……….. 
 
……….. 
 
……….. 
 
………… 
 
………... 
 
………… 
 
…………. 
 
…………. 
 
…………. 
 
…………. 
 
Action 
by when  
 
……….. 
 
……….. 
 
……….. 
 
……….. 
 
……….. 
 
……….. 
 
……….. 
 
………… 
 
………… 
 
………… 
Done? 
 
 
 
………. 
 
………. 
 
………. 
 
………. 
 
………. 
 
………. 
 
……….. 
 
……….. 
 
……….. 
 
……….. 
STEP 5 REVIEW DATE:…………………………• Review the assessment to make sure you are still improving 
 • If there is a significant change, or there has been an accident, check the Assessmen t 
and where necessary,
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